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INTRODUCTION 
Siddha system of medicine is a potent and unique indigenous system of medicine, 
which deals with the diseases of men efficiently with the knowledge of both subtle and also 
the gross material body. The main aim of Siddhars is attaining eternal things through 
spirituality. They found diseases as one of the obstacles to reach spiritual. So they bestowed 
to the world the Siddha medicines to cure diseases.  
They had investigated that the body, though transient was the one and only instrument 
for attaining success in the spiritual development and growth and so worked out to attain the 
eight supernatural powers, as Anima, Magima, Lagima, etc., essential for their goal, as 
mentioned in Silappathigaram. They further realized that if the body could only be made 
strong and perfect they could get rid of birth and death and live for ages together. They are 
the greatest men holding tremendous powers in themselves by way of yoga practice and 
rejuvenation. They are capable of enjoying spiritual success in their mortal bodies. 
According to Siddha science, the human body is composed of five elements viz., 
Earth, Water, Fire, Air and Ether. This is in fact just takes place in the case of dead bodies. 
The following instances will show the transformed conditions of the five elements in the 
human body: 
1. Earth - Bones, flesh, nerves, Skin and Hair. 
2. Water - Bile, Blood, Semen, Secretion and Sweat 
3. Fire - Hunger, Thirst, Sleep, Beauty and Indolence. 
4. Air - Contraction, Expansion and Motion. 
5. Ether - Interspaces of the stomach, Heart and the Head.                   
All earthly things live, move, grow and die to be resolved themselves again into five 
elements after death. They are the fundamental principles of creation, preservation and 
destruction in the universe. On examine their functions, it should be known first, that these 
elements first combine with one another to form cells, the requiste materials or organism for 
the animal body; and secondly, they discharge the functional forces called cellular activities, 
which are in themselves, the guiding principles of mind and the body. 
1. The creative activity in the physical body is known as Vaatham. 
2. The protective one as Pitham. 
3. The destructive one is Kabam. (Phelgm)  
In normal healthy condition these three vital humours exists with the ratio of 1:1/2:1/4 
respectively,  when the normal of these humours disturbed, disease will occur. 
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According to Siddha literature, Azhal Keel Vayu is one among the Vaatha diseases. 
Normally joints are considered to be the place for the vital humour called Iyam. When it is 
affected by deranged Vaatham and Pitham it will leads to Azhal Keel Vayu and it is 
characterized by pain, swelling and restricted movements. Sometimes it may leads to 
difficulty in walking. 
This condition can be correlated to Osteoarthritis in Modern Orthopedics. 
Osteoarthritis is defined as a degenerative, non - inflammatory joint disease characterized by 
destruction of articular cartilage and formation of new bone at the joint surfaces and margins. 
Recent study suggests that Osteoarthritis beats all other most prevalent diseases. 
Primary osteoarthritis is a common disorder of the elderly, and patients are often 
asymptomatic. Approximately 80-90% of individuals older than 65 years have evidence of 
primary osteoarthritis. Patients with symptoms usually do not notice them until after age 50 
years. The prevalence of the disease increases dramatically among persons over age 50, likely 
because of age-related alterations in collagen and proteoglycans that decrease the tensile 
strength of the joint cartilage and because of a diminished nutrient supply to the cartilage. 
There is considerable number of patients reporting daily for the treatment for Azhal 
Keel Vayu in National Institute of Siddha. Hence the author has chosen this disease for 
Dissertation study. 
 In Siddha literatures, many poly herbal and herbo mineral formulations were 
mentioned for this particular condition. Hence the author is interested to try cost effective 
remedy to the patients as said in Siddha literatures which the application of basic principles 
of Siddha and also supporting by Modern parameters. 
The drugs Avuri Karpam (Internal drug, Reference: Pathartha Guna Vilakkam; Pg 
no: 43) and Vatha Noikku Ennai (External drug, Reference: Theraiyar Vagadam; Pg no: 64) 
are indicated for Vaatha diseases including Azhal Keel Vayu. These drugs have not so far 
been evaluated for Azhal Keel Vayu. 
 Hence the author has chosen “Avuri Karpam” as internal drug and and “Vatha 
Noikku Ennai” for external application to evaluate their efficacy in treating Azhal Keel Vayu 
(Osteoarthritis) along with varmam. 
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AIM AND OBJECTIVES 
Primary objective 
· To evaluate the Therapeutic efficacy of “Avuri Karpam”(Internal medicine) and “Vatha 
Noikku Ennai” (External medicine) in the Treatment of “Azhal Keel Vayu” (Osteoarthritis) 
for the reduction of pain, swelling and to improve the range of movements. 
Secondary objectives:   
· To study the effectiveness of Varmam along with the efficacy of “Avuri Karpam” (Internal 
medicine) and “Vatha Noikku Ennai” (External medicine) in the Treatment of “Azhal Keel 
Vayu (Osteoarthritis)”. 
· To study Azhal Keel Vayu, on the basis of Siddha principles like Envagai thervu, 
Mukkutram, Kaalam, Naadi, Neerkkuri, Neikkuri etc, in order to evaluate the pathology. 
· To access the predominance of the disease related to age, sex, socio-economic status, habits, 
family history etc. 
· To evaluate the safety of the trial drug by doing toxicological studies in animal models. 
· To find out any side effect/adverse effect during the trial.  
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SIDDHA ASPECTS 
             The concepts of Siddha system are based on fundamental principles of 96 -
Thathuvams. Vaatham, Pitham, Kabam  are called as three humours of the human system. 
When the hormony of the above said humours gets deranged owing to a relative increase or 
decrease of one or more of the principal humours, disease is caused. The normal ratio of 
Vaatham, Pitham and Kabam is 1: 1/2:1/4 respectively. It is explained in the following verse, 
         "ÅÆí¸¢Â Å¡¾õ Á¡ò¾¢¨Ã ¦Â¡ýÈ¡¸¢ø 
          ¾Æí¸¢Â À¢ò¾ó ¾ýÉ¢Ä¨Ã Å¡º¢ 
          «ÆíÌí ¸Àó¾¡É¼í¸¢§Â ¸¡§Ä¡Êø 
          À¢Èí¸¢Â º£Å÷ìÌõ À¢º ¦¸¡ýÚÁ¢ø¨Ä§Â" 
       - Ì½Å¡¸¼õ. 
The alteration in the normal produces disease. The signs and symptoms are produced 
according to the particular deranged kuttrams. 
AZHAL KEEL VAAYU 
In Siddha literature Azhal keel vaayu described under Vaatha diseases. Keel vaayu is 
the general term that includes all kinds of joint disorders. 
Description of the nomenclature 
Azhal keel vaayu        =   Azhal + Keel + Vaayu 
Azhal              =   Pitham 
Keel                 =   Joint 
Vaayu             =   Vaatham 
Initially the joint is affected by the vitiated Vaatham. Pitham and Kabam accompany 
later. It is a disease which is common in Pitha kaalam (middle 1/3 of the lifespan). 
TYPES OF KEEL VAAYU 
Azal keel Vaayu is one among the ten types of Keel vaayu, which is mentioned in the 
text Siddha Maruthuvam, the ten types of  Keel vaayu are: 
1. Vali keel vaayu 
2. Azhal keel vaayu 
3. Iyya keel vaayu 
4. Vali  Azhal keel vaayu 
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5. Vali  Iyya keel vaayu 
6. Azhal Vali keel vaayu 
7. Azhal Iyya keel vaayu 
8. Iyya Vali keel vaayu  
9. Iyya  Azhal keel vaayu 
10. Mukkutra keel vaayu 
AETIOLOGY: 
1. Environmental factors: 
"Å¡¾ Å÷ò¾É ¸¡Ä§Á§¾¡ ¦ÅýÉ¢ø 
ÁÕ×¸¢ýÈ ¬É¢ ¸ü¸¼ Á¡¾õ 
¬¾¨Éô Àº¢§Â¡Î ¸¡÷ò¾¢¨¸ ¾ýÉ¢ø 
¬¼Õ§Á ÁüÈ Á¡¾í¸û ¾ýÉ¢ø 
§À¡¸§Å ºÁ¢ì¸¢ýÈ ¸¡Ä Á¡Ìõ". 
                                           - ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
It is said that the Vaatha diseases are precipitated in the months from Aani to 
Karthigai (June to December), hence the seasonal factors are involved and facilitate the 
Vaatha diseases. 
2. Diets that increase Vaatha diseases: 
 
"ÅÇ¢ ¸¡ö¸¢ÆíÌ Å¨ÃÅ¢Ä¡ ¾Á¢Äø §¸¡¨Æ 
ÒÇ¢¾Â¢÷ §À¡ýÁ¢ÕìÌ Ó¨ÈÂ¢Ä¡ ×ñÊ §¸¡¼ø 
ÌÇ¢÷ ¾Õ ÅÇ¢Â¢ü §È¸í ÌÉ¢ôÒÈ ×ÄÅø ¦ÀñÊ÷ 
ÌÇ¢¾Õ ÓÂì¸õ ¦Àü§È¡÷ ¸Ê¦ºÂø ¸ÕÅ¢Â¡Á¡ø". 
     - ºÀ¡À¾¢ ¨¸§ÂÎ  
      “¦¾¡Æ¢ø ¦ÀÚ ¨¸ôÒì ¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢íÍ¸¢Ûí§º¡Úõ 
       À¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô ¨Àó¾¢¨É ÂÕó¾¢É¡Öõ 
       ±Æ¢ø ¦ÀÈô À¸ÖÈí¸¢ þÃÅ¢É¢ÖÈí¸¡¾ ¾¡Öõ 
       Á¨Æ¿¢¸¡ ÌÆÄ¢É¡§Ä Å¡¾í§¸¡ À¢ìÌí ¸¡§½". 
                                              - ÀÃÃ¡º §º¸Ãõ 
Vaatha disease is caused by the following reasons: 
· Excessive  intake of  tubers 
· Excessive  intake of chill foods 
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· Excessive intake of  bitter, astringent, acrid taste foods 
· Intake of varagu, thinai. 
· Wandering in chill air 
· Getting drenched in rain 
· Living in hilly region 
· Heredity and 
· Altered sleep pattern also contribute to Vaatha disease. 
3. Habits:  
“¾¡¦ÉýÈ ¨¸ô§À¡Î ÐÅ÷ôÒÅ÷ôÒ 
º¡¾¸Á¡ö Á¢ïÍ¸¢Öõ º¨Áò¾ «ýÉõ 
¬¦ÉýÈ ¬È¢ÉÐ Òº¢ò¾Ä¡Öõ 
¬¸¡ºò §¾üÈ¿£÷ ÌÊò¾Ä¡Öõ 
Â¡¦ÉýÈ À¸ÖÈì¸õ þÃ¡Å¢Æ¢ôÒô 
ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã¦Áö¾ø 
§¾¦ÉýÈ ¦Á¡Æ¢Â¡÷ §Áø º¢ó¨¾Â¡¾ø 
º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó¾¡§É” 
-ä¸¢ÓÉ¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
"¦ÅöÂ¢Ä¢ø ¿¼ì¨¸Â¡Öõ Á¢¸ì¾ññ£÷ ÌÊì¨¸Â¡Öõ 
  ¦ºöÂ¢¨Æ Á¸Ç¢É¨Ãî §º÷ó¾ÛÀ Å¢ì¨¸Â¡Öõ 
  ¨ÀÂ§É ¯ñ¨ÁÂ¡Öõ À¡¸ü¸¡ö ¾¢ý¨¸Â¡Öõ 
  ¨¾Â§Ä Å¡¾§Ã¡¸õ ºÉ¢ìÌ ¦ÁýÈÈ¢óÐ ¦¸¡û§Ç". 
                                               - §¾¨ÃÂ÷ Å¡¸¼õ 
The factors like, excessive walking in sun and excessive in take of bitter guard etc, 
also disturbs the normal functions of Vaatham. 
4. Involvement of Mukkutram ie Vaatham, Pitham and Kabam: 
· Abanan and Viyanan are affected in Vaatham. 
· In Pitham, Sathaga pitham is affected. 
· Santhigam is affected in Iyyam.  
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5. Characteristic features of Vaatham: 
“Å¡¾§Á ¸¾¢ò¾ §À¡Ð Å¡Ô×¦ÁØõÒí ¸¡ñÀ£÷ 
Å¡¾§Á ¸¾¢ò¾ §À¡Ð Å¡ÔÅó¾¢Îï ºýÉ¢ §¾¡„õ 
Å¡¾§Á ¸¾¢ò¾ §À¡Ð ÅøÄÎý ¦ÁÄ¢óÐ ¦¸¡øÖõ” 
                                - «¸ò¾¢Â÷ º¢¸¢îº¡ ÃòÉ¡ ¾£Àõ 
“Å¡¾ Å£Ú «ýÉÁ¢Èí¸¡Ð ¸ÎôÒñ¼¡õ Åñ½Óñ¼¡õ 
§Á¡Ð¸ðÌ §Ã¡¸õ ÍÃÓñ¼¡ Á¢ÕÁÖÁ¡ ÓÈí¸¡¦¾ýÚõ 
µ¾Ã¢Â Å¡¾ÁÉÄ¡Ì ¿Îì¸Óñ¼¡õ ¦À¡Õû ¸ÇÂ÷ó¾ 
¾£¦¾É§Å ¿ÃõÀ¢òÐ ºóÐ¸û §¾¡Úí¸¼ìÌó ¾¢ÉÓó¾¡§É" 
                                            - §¾¨ÃÂ÷ Å¡¸¼õ 
When the Vaatha kuttram aggravates in will produce the following signs and symptoms:  
· loss of appetite,  
· excruciating pain,  
· fever,  
· cough,  
· insomnia,  
· shivering of the body,  
· nervous weakness,  
· Joint pain. 
Clinical features of Keel Vayu: 
"À¢ò¾ ¸£øÅ¡Ô ¾ýÉ¡ü ¸£øãðÎÅ£í¸¢î 
  º¢ò¾÷ ¦ºöÁÕòÐÅî º£÷À¼¡¾ 
  ¾ì¸Ú ¸¡öîºø ¸ñÎ º¡Ä§Å ¾¨É¾¡É ¾ó§¾ 
¦Áò¾Ú º¢¸¢î¨º ¾ýÉ¾ø ¦Áý§Áø ¿£ìÌÁôÀ¡" 
                                      - ºÀ¡À¾¢ ¨¸§ÂÎ 
It is characterized by swelling of joints associated with severe pain and fever.  
Since it is not quickly responding to medicine the prolonged medical care is said to be 
essential.  
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Diagnosis in Siddha: 
Piniyari muraigal (Method of Diagnosis) is based upon three main principles, 
1. Poriyal Arithal 
2. Pulanal Arithal 
3. Vinaathal   
1.  Poriyal Arithal (Inspection): 
  “Poriyal arithal” means examining the “Pori” of the patient by the “Pori” of the 
physician for proper diagnosis. Pori is considered as the “Five sense organs” of perception 
namely, 
1. Mei  (Skin)  
2. Vai  (Tongue) 
3. Kan  (Eye) 
4. Mookku   (Nose) 
5. Sevi   (Ear) 
2. Pulanal arithal (Palpation): 
            Pulanal arithal means examining the “Pulan” of the patient by the “Pulan” Physician 
to diagnose a disease.  Pulan are five senses. They are, 
1. Smell 
2. Taste 
3. Vision 
4. Sensation of touch 
5. Hearing 
3. Vinaathal (Interrogation): Vinaathal is gathering information regarding the history of 
disease, its clinical features etc., from the patient or his/her close relatives useful when the 
patient is not in a position to speak or in the case of a child. 
ENVAGAI THERVUGAL (Eight diagnostic Tools): 
          It is a unique method of diagnosis in Siddha system of medicine. They are clearly 
explained by Siddhar Theraiyar; 
"¿¡Ê ŠÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢ 
ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅÃ¡Ô¾õ" 
                           - §¾¨ÃÂ÷ 
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1. Naadi (Pulse): 
“¾¢Õò¾Á¡õ Å¡¾ò§¾¡§¼ ¾£í§¸¡Î À¢ò¾õ §ºÃ¢ü 
 ¦À¡ÕòÐ¸û §¾¡Úõ ¦¿¡óÐ §À¡¾§Å À¢ÊìÌõ” 
                                       - §¿¡Â¢ý º¡Ãõ 
“Å¡ðÊÎõ §ºòÐÁò¾¢ø Åó¾¢Îõ Å¡¾Á¡¸¢ø  
 ¿¡ðÊÂ ¸¡ø¸û §À¡Ä ¿Ãõ¦ÀøÄ¡õ ÅÄ¢òÐ ¿¢üÌõ” 
      -«¸ò¾¢Â÷ ¿¡Ê 
In Azhal Keel Vaayu the following Naadi can be seen commonly: 
            Vaathapitham, Vaathakabam, Pithavaatham, Pithakabam, Kabavaatham 
2. Sparism (Sensation to touch): 
In Azhal keel vaayu mild warmth noticed over the affected joint. 
3. Naa (Tongue): 
In Azhal keel vaayu no abnormality is seen in Naa. 
4.  Niram (Colour): 
 In Azhal keel vaayu no abnormality is seen in Niram. 
5. Mozhi (Voice): 
In Azhal keel vaayu no abnormality is seen. 
6. Vizhi (Eyes): 
In Azhal keel vaayu no abnormality is seen. 
7. Malam (Faeces): 
In Azhal keel vaayu constipation was reported in some cases. 
8. Moothiram (Urine): 
In urine (Moothiram) Neerkkuri and Neikkuri (Oil on urine sign) examination are also 
done. 
a. Neikkuri: 
"«ÕóÐ Á¡È¢Ã¾Óõ «Å¢§Ã¡Á¾¡ö 
       «·¸Ä «ÄÅ÷¾ø «¸¡Äçý ¾Å¢÷ó¾Æü 
       ÌüÈÇ ÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
       ¬Êì ¸Äºò ¾¡Å¢§Â ¸¡Ð¦Àö 
       §¾¡Õ ÓÜ÷ò¾ì ¸¨ÃÌð ÀÎ¿£Ã¢ý 
       ¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É" 
                                     - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ    
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Prior to the day of urine examination the patient is instructed to take a balanced diet 
and quantities of food must be proportionate to his routine intake. The patient could have no 
disturbed sleep. After waking up in the morning, the first urine voided is collected in a clear 
wide mouthed glass dish or China clay container and is subjected to analysis of “Neerkkuri 
and Neikkuri” within one and a half an hour. 
The collected specimen was examined by the following method. The collected urine 
specimen is kept in a glass dish or china clay container and observed under direct sunlight 
without shaking the vessel. Then drip one drop of gingely oil and observe the spreading 
pattern and concludes as follows,  
 "«Ã¦ÅÉ ¿£ñËÊý «·§¾ Å¡¾õ 
 ¬Æ¢§À¡ø ÀÃÅ¢ý «·§¾ À¢ò¾õ 
 Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á 
 «ÃÅ¢ø ¬Æ¢Ôõ ¬Æ¢Â¢ø «Ã×õ  
 «ÃÅ¢ø ÓòÐõ ¬Æ¢Â¢ø ÓòÐõ" 
- º¢ò¾ ÁÕòÐÅ §¿¡ö¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ  
b. Neerkkuri: 
 "Åó¾ ¿£÷ì¸Ã¢ ¨Â¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
   ¨Èó¾¢Â ÖÇ¨Å Â¨ÈÌÐ Ó¨È§Â" 
                                          - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ  
Urine is examined for the following neerkkuri: 
· Niram     -  Colour  
· Edai         - Specific Gravity 
· Manam   -  Smell 
· Nurai       - Frothy nature 
· Enjal        -  Quantity of urine voided 
Apart from these, frequency of urination, abnormal constituents, such as sugar, 
protein, presence of blood, pus, presence of crystals also to be found out. 
         In Azhal keel vaayu straw or hay coloured urine was noticed in Neerkkuri. 
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PARUVAKAALAM (Seasonal variations): 
"Å¡¾Å÷ò¾¨É ¸¡Ä¦Á§¾¡ ¦ÅýÉ¢ø 
  ÁÕ×¸¢ýÈ ¬É¢¸ü ¸¼Á¡Ìõ 
¬¾ «üÀº¢§Â¡Î ¸¡÷ò¾¢¨¸ ¾ýÉ¢ø 
  «¼Õ§Á ÁüÈÁ¡¾í¸û ¾ýÉ¢ø 
§À¡¾§Å ºÁ¢ìÌ¸¢ýÈ ¸¡ÄÁÌõ 
  ¦À¡Õó¾¢§Â Â¢Å÷¦¾¡Æ¢ø¾¡ý ¸ñ¾¢Èò¾ø 
¸¡¾§Å ¸ñã¼ø ¨¸¸¡Ä¨ºò¾ø  
  ¸Êó¦¾¡ð¼ Ó¼ì¸§Ä¡Î ¿£ð¼¦Äý§É" 
       -ä¸¢ÓÉ¢ ¨Åò¾¢Â º¢ó¾¡Á½¢            
Sl. 
No STATE OF KUTTRAM KAALAM 
1. Vaatham  thannilai  adaithal                Munpani kaalam, Pinpani kaalam,Koothir kaalam, 
Elavenil kaalam                                                                   
2. Vaatham thannilai valarchi Muthuvenil kaalam 
3. Vaatham vetrunilai valarchi Karkaalam 
 
 
THINAI (Geographical Distribution): 
 
It is divided into five types. They are, 
· Kurinji        -   Mountainous regions and surroundings 
· Mullai         -   Forest region and surroundings 
· Marutham   -   Paddy  fields and surroundings 
· Neithal       -   Sea and coastal regions 
· Palai           -    Desert land 
        Geographical distribution plays a vital role in altering Mukkutrams. According to 
Siddha, Vaatha diseases are predominant in Mullai and Neithal Thinai. 
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UDAL KATTUGAL: 
Our body consists of seven Udal kattukal. It gives strength and structure to our body. 
Their functions are: 
SL. 
No 
UDAL 
KATTUGAL FUNCTIONS 
1. Saaram   It gives strength to the body and mind. 
2. Senneer                           Saram after absorption is converted into senneer. It is responsible for 
knowledge strength, boldness and healthy complexion. 
3.  Oon                                  Gives structure and shape to the body and is responsible for the 
movements of the body. 
4.  Kozhuppu Lubricates the organs on its own works. 
5.  Enbu Protects the vital organs and used for movements and nominates the 
body structure. 
6.  Moolai Absent  inside the bones and it gives strength and maintains the 
normal Condition of the bone. 
7.  Sukkilam(or)  
suronitham                                   
Responsible for the reproductive function of species. 
 
          
 
SL. 
No 
UDAL  
KATTUKAL 
INCREASED CONDITIONS DECRESED CONDITIONS 
1. Saaram                     Loss of appetite, excessive 
salivation                
Tiredness, Laziness, 
Diminished activity of the 
sense organs. 
2. Senneer Boils and tumours in different                                
Parts of the body, Splenomegaly, 
Colic pain, increased blood           
Pressure, reddish eye and skin,                                     
Tiredness, Lassitude,                       
Anaemia 
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3. Oon Tumours or extra growth around                
 the neck, face, abdomen, thigh.    
Genitalia etc., 
Muscle wasting 
 
4. Kozhuppu                     Tumours or extra growth around  
the neck, face, abdomen, thigh,                                          
Genitalia etc., with dyspnoea and 
Pain 
5.  Enbu                              Strong bones and teeth Weak bones, teeth, nails and 
hair.      
6.  Moolai                       Heaviness, swollen eyes,                                   
Swollen phalanges, oliguria  and 
Osteoporosis and shrunken 
eyes 
7. Sukkilam or                     
Suronitham                     
Increased sexual activity and                             
 signs identical to urinary calculi                             
Failure to reproduce,                                            
pain in genitalia  
 
In Azhal keel vaayu,  
Saaram, Kozhuppu, Moolai and Enbu thathukkal are commonly affected. 
           Saaram:        Weakness, pain in knee joints 
             Kozhuppu:    Morning stiffness occurs in affected knee joints 
 
 Enbu:             Pain occurring in affected knee joints, crepitations Absent  
 
Moolai:          Inflammation, degeneration, swelling etc.  
 
MUKKUTRAM: 
             Human body is influenced by Mukkutrams ie Vaatham, Pitham and Kabam. They are 
responsible for normal physiological conditions of the body. Vaatham is mainly responsible 
for proper loco-motor functions. Bones and joints are considered to be the main location of 
vaatha.  
             In Azhal keel vaayu the vaatha kutram is mainly affected followed by Pitham and 
Kabam. This produces the following signs and symptoms, 
· Deranged Viyanan leads to pain and difficulty in movements. 
· Deranged Abanan leads to constipation. 
· Inflammatory changes of the joints, redness and warmth are developed due to 
deranged Pitham. 
· Sathaga Pitham gets affected hindering the loco motor functions. 
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· Along with Vaatham, Kabam is also deranged, Santhikam is affected and this leads to 
abnormality in joint movements. 
· Erosions of bone margin, increased secretion of synovial fluid are developed due to 
deranged fluid are developed due to deranged Kabam. 
 
  NAME       LOCATION PHYSIOLOGIC FUNCTIONS 
Abanan Lower abdomen and 
Extremities 
Responsible for urination, defecation and parturition, 
Menstruation, ejaculation of the sperm. 
Viyanan Heart  Responsible for movements of all parts of the body 
and sensation. 
Samanan Stomach Responsible for proper   digestion      
 
VAATHAM: 
In Azahal keel vaayu 
· Abanan is affected and so constipation is produced. 
· Viyanan is affected it renders difficulty in movements of the knee joints. 
· Samanan is also affected because disturbed state of other Vaayus. 
PITHAM: 
  In Azhal keel vaayu, Sathaga Pitham affected and produces difficulty in walking, 
climbing upstairs, squatting and sitting postures. 
KABAM: 
Kaba kutram stabilizes and maintains the movements of the joints and gives 
lubrications to all movements.  
      In Azhal keel vaayu Santhigam is affected and produce difficulty in movements of the 
knee joints. 
IMPORIGAL:  
           Gnanenthiriyam are Mei, Vaai, Kan, Mooku and Sevi. 
         In Azhal keel vaayu no abnormalities are seen in Gnanenthiriyam. 
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KANMENTHIRIYAM:  
             Kanmenthiriyam are Kai, Kaal, Vaai, Eruvaai, Karuvai. 
           In Azhal keel vaayu “Kaal” is affected and  because of pain and swelling, morning 
stiffness and deformities. 
NOI KANIPPU VIVATHAM (DIFFERENTIAL DIAGNOSIS): 
              Azhal keel vaayu is differentiated from the followings diseases, 
1. VALI KEEL VAAYU: 
  It is characterized by excruciating pain and swelling involving  knee joints, hip 
joints, elbow joints, shoulder joints and associated with systemic disturbances like dryness of 
mouth, pyrexia, headache, palpitation, constipation and sweating. In advanced cases it may 
affect the heart and produce “Thamaraga vaayu”. 
2. IYA KEEL VAAYU: 
It is characterized by severe pain in the joints associated with emaciation of the body, 
anorexia, insomnia, cough, hiccough, vomiting, anaemia and dropsy. The common sites are 
spinal cord, hip joints and knee joints. 
3. VALI IYA KEEL VAAYU: 
It is characterized by pain in the joints associated with effusions of joint fluid and 
swelling, restricted joint movements, pyrexia, fainting, insomnia, especially in knee joint 
asymmetrically, lymphadenopathy, generalized malaise, atrophy of the affected limb etc.  
The affected joint looks like “Fox’s Head”. 
LINE OF TREATMENT 
              In Siddha system the main aim of the treatment is to cure Udarpini (due to 
Mukkuttram) and Manapini (due to changes in Mukkunam). Treatment is not only for perfect 
healing but also for the prevention and rejuvenation. 
It is essential to know the disease, the aetiology, the nature of the patient, severity of 
the illness, the seasons and the time of occurrence must be observed clearly. 
Line of treatment is as follows: 
1. Neekkam (Treatment) 
2. Niraivu   (Rejuvenation) 
3. Kaapu  (Prevention) 
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               Thiruvalluvar describes the duty of the physician, i.e. study the disease, aetiology, 
seek subsiding ways and do what is proper and effective. 
            "§¿¡ö ¿¡Ê §¿¡ö Ó¾ø ¿¡Ê «Ð ¾½¢ìÌõ 
          Å¡ö ¿¡Ê Å¡öôÀî ¦ºÂø" 
    "¯üÈ¡ÉÇ×õ À¢½¢ÂÇ×í ¸¡ÄÓõ 
          ¸üÈ¡ý ¸Õ¾¢î ¦ºÂø" 
                                     - ¾¢ÕìÌÈû. 
1)  NEEKKAM (Treatment in Siddha): 
The aim of Neekkam is based on 
· To bring the deranged Thodams to normal equilibrium state. 
· To treat the patient with internal medicine and external medicine. 
 Siddha system of Medicine is based on Mukkutra Theory and hence the treatment is 
mainly aimed to bring the three thodams to equilibrium state and thereby restoring the 
physiological condition of the seven Thathus. 
 The three Thodams organise, regularise and integrate the body structure and their 
functions. They are always kept in a state of balance by thought, word, deed and food. Any 
imbalance will lead to disease. The imbalanced thodams are balanced by administrating 
purgatives or emetics or application of Anjanam (application on eyes) and followed by the 
appropriate systemic therapy by giving Siddha drugs. It mentioned as below: 
       "Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ" 
             "ÅÁÉò¾¡ø À¢ò¾õ ¾¡Øõ" 
              "¿º¢Â «ïºÉò¾¡ø ¸Àõ ¾¡Øõ" 
                  - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
    The purgatives should be given before starting the trial to normalize the deranged 
Thodams to normal.  
     In this study the purgation is induced by giving Agasthiyar kulambu - 130 mg with 
hot water in early morning in empty stomach on the first day. 
 Then the next day onwards the trial drugs Avuri karpam – 1gm twice a day given with 
honey after food. Vatha Noikku Ennai – External application. 
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2)  NIRAIVU (Rejuvenation): 
The word literally means the power of securing the body from the effect of 
age.According to Siddhars science rejuvenation does not necessarily mean restoring the old 
to youth for it may simply mean the maintenance of youth without  reaching the old age. 
So rejuvenation is a means for prolonging life & forms a part of immortality. 
-  T.V. Sambasivam pillai dict.  
 (Physical, psychological, social and economic rehabilitation and reassurance of 
individuals is known as Niraivu). 
3) KAPPU (Prevention): 
           The prevention methods for Azal keel vaayu are as follows: 
· Control the body weight by diet and exercise. 
· Modify the nature of work which gives stress to a particular joint.  
e.g. - Avoid prolonged standing and long distance walking. 
· Avoid to intake excess sour, astringent and bitter tasted foods. 
4)  DIETARY RESTRICTIONS: 
In siddha system of medicine the importance of dietary habits also emphasiszed for 
the diseases management and prevention. This line is well understood in these verses, 
“¯½§Å ÁÕóÐ ÁÕó§¾ ¯½×”. 
“ÁÕó¦¾É §Åñ¼¡Å¡õ Â¡ì¨¸ìÌ «Õó¾¢ÂÐ 
«üÈÐ §À¡üÈ¢ ¯½¢ý”. 
                               - ¾¢ÕìÌÈû  
In diseased condition diet restrictions or paththiyam are strictly followed to increase 
the effectiveness of medicine, and to reducing the severity of diseases.  This is given in the 
following verse,  
 “Àò¾¢Âò¾¢É¡§Ä ÀÄý ¯ñ¼¡Ìõ ÁÕóÐ 
Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ - Àò¾¢Âò¾¢ø 
Àò¾¢Â§Á ¦ÅüÈ¢¾Õõ ÀñÊ¾÷ìÌ ¬¾Ä¢É¡ø 
Àò¾¢Â§Á ¯ò¾¢¦ÂýÚ À¡÷” 
                            - §¾¨ÃÂ÷ ¦ÅñÀ¡. 
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þîº¡ Àò¾¢Âò¾¢ø ¿£ìÌõ ¦À¡Õð¸û: 
"¸ÎÌ ¿üÈ¢Äò ¦¾ñ¨½ö ÜúÀ¡ñ¼í¸û ¸¼¨Ä 
ÅÕÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸ ¿ü¸¡Âõ 
ÁÊÅ¢Ä¡¾ ¦ÅûÙûÇ¢¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
þ¼Ú À¡¸§Ä¡ ¼¸ò¾¢ ¿£ì¸¢¼Ä¢îº¡ Àò¾¢Âõ" 
                                          - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
¸ÎÌ, ±û¦¿ö, ¸øÂ¡½âº½¢ì¸¡ö, ¸û, ¸¼¨Ä, §¾í¸¡ö, Á¡í¸¡ö, ÀÄ¡, 
¸¡Âõ, ¯ûÇ¢ôâñÎ, ¦¸¡û, Ò¨¸Â¢¨Ä, ¦Àñ¸û §º÷ì¨¸, À¡¸ø, «¸ò¾¢ 
þ¨Å¸¨Ç þîº¡ Àò¾¢Âò¾¢ø ¿£ì¸ §ÅñÎõ. 
         "ÒÇ¢ÐÅ÷ Å¢ïÍõ ¸È¢Â¡ø âÃ¢ìÌõ Å¡¾õ" 
                                  - §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ 
ÒÇ¢ôÒ, ÐÅ÷ôÒ Í¨ÅÔûÇ  ¯½× Å¨¸¸¨Ç ¿£ì¸ §ÅñÎõ. 
ÁÕòÐÅ «È¢×¨Ã: 
· ®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ, 
· ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É þ¼ò¾¢ø þÕôÀ¨¾ò ¾Å¢÷ì¸×õ. 
· ¯¼ø «¾¢¸ ±¨¼ þÕôÀ¢ý ±¨¼¨Âì Ì¨Èì¸ §ÅñÎõ. 
· «¾¢¸ àÃõ ¿¼ò¾ø, «¾¢¸ §¿Ãõ ¿¢üÈø ¾Å¢÷ì¸×õ. 
Special treatments: 
Varmam: 
Varmam is a science dealing with the impact to innumerable nerve junctions of the 
human body.  The changes occurring in the body on being hit at some specific points on the 
body directly or indirectly with a particular force is known as varmam. 
VARMAM POINTS TO BE MANIPULATED ONCE EVERYDAY IN AZHAL KEEL 
VAYU PATIENTS: 
· Kaal Moottu Varmam  
· Moottu Suzharchi Varmam 
· Komberi 
· Viruthi 
· Ullangal vellai 
· Kutri Varmam .    
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MODERN ASPECTS 
ANATOMY OF JOINTS: 
Joints can be classified as synovial, fibrous, or combination joints, based on the 
presence or absence of a synovial membrane and the amount of motion that occurs in the 
joint. Normal synovial joints allow a significant amount of motion along their extremely 
smooth articular surface. The joints are composed of the following:  
· Articular cartilage 
· Subchondral bone 
· Synovial membrane 
· Synovial fluid 
· Joint capsule. 
The normal articular surface of synovial joints consists of articular cartilage 
(composed of chondrocytes) surrounded by an extracellular matrix that includes various 
macromolecules, most importantly proteoglycans and collagen. The cartilage protects the 
underlying subchondral bone by distributing large loads, maintaining low contact stresses, 
and reducing friction at the joint.  
Synovial fluid is formed through a serum ultra filtration process by cells that form the 
synovial membrane (synoviocytes). Synovial cells also manufacture the major protein 
component of synovial fluid, hyaluronic acid (also known as hyaluronate). Synovial fluid 
supplies nutrients to the avascular articular cartilage; it also provides the viscosity needed to 
absorb shock from slow movements, as well as the elasticity required to absorb shock from 
rapid movements.  
ANATOMY OF THE KNEE JOINT 
 Introduction: 
               The knee joint is the largest joint in the body, consisting of four bones and an 
extensive network of ligaments and muscles. Injuries to the knee joint are amongst the most 
common in sporting activities and understanding the anatomy of the joint is fundamental in 
understanding any subsequent pathology. 
Bones of the knee joint: 
The knee is made up of four main bones. The femur (thigh bone), the tibia (shin 
bone), fibula (outer shin bone) and patella (kneecap). The main movements of the knee joint 
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occur between the femur, patella and tibia. Each are covered in articular cartilage which is an 
extremely hard, smooth substance designed to decrease the frictional forces as movements 
occurs between the bones. The patella lies in an indentation at the lower end of the femur 
known as the inter-condylar groove. At the outer surface of the tibia lies the fibula, a long 
thin bone that travels right down to the ankle joint. 
              Anatomy of the knee joint (right)                   
            
The capsule: 
          The knee joint capsule is a thick ligamentous structure that surrounds the entire knee. 
Inside this capsule is a specialized membrane known as the synovial membrane which 
provides nourishment to all the surrounding structures. Other structures include the infra-
patellar fat pad and bursa which function as cushions to exterior forces on the knee. The 
capsule itself is strengthened by the surrounding ligaments. 
Ligaments of the knee joint: 
The stability of the knee owes greatly to the presence of its ligaments. Each has a 
particular function in helping to maintain optimal knee stability in a variety of different 
positions. 
Menisci (knee cartilage): 
      Each knee joints has two crescent shaped cartilage menisci. These lie on the 
medial and lateral edges of the upper surface of the tibia bone. They are essential 
components, acting as shock absorbers for the knee as well as allowing for correct weight 
distribution between the tibia and the femur.  
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                                    Ligaments knee joints 
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Muscle groups surrounding the knee joint: 
The two main muscle groups of the knee joint are the quadriceps and the hamstrings. 
both play a vital role in moving and stabilizing the knee joint. 
Quadriceps muscle: 
The quadriceps muscle group is made up of four different individual muscles which 
join together forming the quadriceps tendon. This thick tendon connects the muscle to the 
patella which in turn connects to the tibia via the patellar tendon. Contraction of the 
quadriceps, pull the patella upwards and leads to knee extension. 
Hamstrings muscle: 
The Hamstrings muscle function in flexing the knee joint as well as providing 
stability on either side of the joint line. 
        Lateral view  of knee joint 
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OSTEO ARTHRITIS (OA) 
INTRODUCTION: 
Osteoarthritis can be defined as a degenerative, non-inflammatory joint disease 
characterized by destruction of articular cartilage and formation of new bone at the joint 
surfaces and margins. It is a form of arthritis that results in the breakdown and eventual loss 
of the cartilage of one or more joints. Osteoarthritis is abbreviated as OA or referred to as 
degenerative arthritis or degenerative joint disease (DJD). 
EPIDEMIOLOGY: 
International statistics: 
Internationally, osteoarthritis is the most common articular disease. Estimates vary 
among different populations. The prevalence of osteoarthritis differs among different ethnic 
groups. The disorder is more prevalent in Native Americans than in the general population. 
Osteoarthritis of the hip is seen less frequently in Chinese patients from Hong Kong than in 
age-matched white populations. In persons older than 65 years, osteoarthritis is more 
common in whites than in blacks. Knee osteoarthritis appears to be more common in black 
women than in other groups. In India knee arthritis is more common in females than males 
and it is the most frequent joint disease with prevalence of 22 - 39 %. 
Age- and sex-related prevalence: 
Primary osteoarthritis is a common disorder of the elderly, and patients are often 
asymptomatic. Approximately 80-90% of individuals older than 65 years have evidence of 
primary osteoarthritis. Patients with symptoms usually do not notice them until after age 50 
years. The prevalence of the disease increases dramatically among persons over age 50, likely 
because of age-related alterations in collagen and proteoglycans that decrease the tensile 
strength of the joint cartilage and because of a diminished nutrient supply to the cartilage. 
In individuals older than age 55 years, the prevalence of osteoarthritis is higher among 
women than men. Women are especially susceptible to osteoarthritis in the distal 
interphalangeal joints joints of the fingers. Women also have osteoarthritis of the knee joints 
more frequently than do men, with a female-to-male incidence ratio of 1.7:1. Women are also 
more prone to erosive osteoarthritis, with a female-to-male ratio of about 12:1.  
At age 18-24 years, 7% of men and 2% of women show signs of osteoarthritis in the 
hands. At age 55-64 years, 28% of men and women show signs of osteoarthritis in the knee, 
and 23% show signs of osteoarthritis in the hip. At age 65-74 years, 39% of men and women 
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show signs of osteoarthritis in the knee and 23% show signs of osteoarthritis in the hip. At 
age 75-79 years, approximately 100% of men and women show some signs of osteoarthritis.  
CLASSIFICATIONS: 
 It could be divided into 2 types 
                  1. Primary or idiopathic osteoarthritis 
                  2. Secondary osteoarthritis 
1. Primary or idiopathic osteoarthritis: 
It is due to wear and tear changes occurring in old age in which the weight bearing 
joints like the hips and knees are more commonly affected.  It is uncommon in non-weight 
bearing joints like the shoulder and elbow.  Obesity is a predisposing factor. 
2. Secondary osteoarthritis: 
 It is due to an abnormal wear and tear in a joint, caused by mechanical incongruity of 
the articular surfaces.  This incongruity is due to the  
· Mal-union of fractures involving the articular surfaces of tibia, femur or patella 
· Loose bodies in the joint 
· Malalignment of the bones due to deformity like genu valgum or genu varum. 
Sites of primary osteoarthritis: 
Common sites: 
· Apophyseal  joint of the  cervical spine 
· Thoraco lumbar spine 
· First carpometacarpal joint 
· Distal interphalangeal joint 
· Patello-femoral joint 
· Tibio-femoral joint 
· First metatarsalphalangeal joint 
Less common sites: 
· Acromio clavicular joint 
· Hip joint 
Uncommon sites: 
· Shoulder joint 
· Elbow joint 
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· Wrist joint 
· Metaphalangeal joint 
· Ankle joint 
Difference between Primary OA and Secondary OA 
PRIMARY OSTEOARTHRITIS SECONDARY OSTEOARTHRITIS 
Usually limited to one or a small 
number of joints. 
May be limited to a small number of joints in injury 
related or may be in joints throughout body, if 
disease related 
No specific inflammatory or 
metabolic condition known to be 
associated with arthritis is Absent . 
Condition that cause damage to cartilage are Absent 
, such as  -  Inherited disease of iron, calcium or 
copper storage such as hemochromatosis, 
Hyperparathyroidism or Wilson’s disease. 
Neurologic disorder that result in the loss of nerve 
function. 
Congenital disease that cause an imbalance in the 
joints.    
No history of specific injury or 
trauma. 
History of injury to joints, such as fractures and 
tears or history of trauma to joints, such as 
repetitive heavy lifting. 
PATHOPHYSIOLOGY: 
In early osteoarthritis, swelling of the cartilage usually occurs, due to the increased 
synthesis of proteoglycans, this reflects an effort by the chondrocytes to repair cartilage 
damage. This stage may last for years or decades and is characterized by hypertrophic repair 
of the articular cartilage.  
As osteoarthritis progresses, however, the level of proteoglycans eventually drops 
very low, causing the cartilage to soften and lose elasticity, thereby further compromising 
joint surface integrity.  
Microscopically, as flaking and fibrillations (vertical clefts) develop along the 
normally smooth articular cartilage on the surface of an osteoarthritic joint, the loss of 
cartilage results in the loss of the joint space.  
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In major weight-bearing joints of persons with osteoarthritis, a greater loss of joint 
space occurs at those areas subjected to the greatest pressures; this effect contrasts with that 
of inflammatory arthritis, in which uniform joint-space narrowing is the rule. In the 
osteoarthritic knee, for example, one commonly observes the greatest loss of joint space in 
the medial femorotibial compartment, although the lateral femorotibial compartment and 
patellofemoral compartment may also be affected. Collapse of the medial or lateral 
compartments may result in varus or valgus deformities, respectively.  
Erosion of the damaged cartilage in osteoarthritic joint progresses until the underlying 
bone is exposed. Bone denuded of its protective cartilage continues to articulate with the 
opposing surface. Eventually, the increasing stresses exceed the biomechanical yield strength 
of the bone. The subchondral bone responds with vascular invasion and increased cellularity, 
becoming thickened and dense (a process known as eburnation) at areas of pressure. The 
traumatized subchondral bone may also undergo cystic degeneration, due to either osseous 
necrosis secondary to chronic impaction or to the intrusion of synovial fluid.  
Osteoarthritic cysts are also referred to as subchondral cysts, pseudocysts, or geodes, 
the preferred European term. These lesions are generally 2-20 mm in diameter. 
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AETIOLOGY OF OSTEOARTHRITIS:  
  The daily stresses applied to the joints, especially the weight-bearing joints (eg, ankle, 
knee, hip), play an important role in the development of osteoarthritis. Degenerative 
alterations in osteoarthritis primarily begin in the articular cartilage, as a result of either 
excessive loading of a healthy joint or relatively normal loading of a previously disturbed 
joint. External forces accelerate the catabolic effects of the chondrocytes and disrupt the 
cartilaginous matrix 
Though exact cause is not known, the following factors are suspected to play an 
important role in the causation of primary osteoarthritis  
1. Endocrine: 
People with Diabetes may be prone to osteoarthritis. Other endocrine problems also 
may promote development, including acromegaly, hypothyroidism, hyper parathyroidism and 
obesity. Menopause often increases the progression of osteoarthritis. 
2. Post Traumatic:  
Traumatic causes can be further divided into macro trauma or micro trauma. An 
example of macro trauma is an injury to the joint such as bone break causing the bones to line 
up improperly (mal alignment), lose of stability or damage cartilage. Micro trauma may occur 
over time (chronically). An example of this would be repetitive movements or the overuse 
noted in several occupations. 
3. Inflammatory Joint Disease: 
This category would include infected joints, chronic gouty arthritis and rheumatoid 
disease. 
 4. Metabolic: 
Disease causing errors of metabolism may cause osteoarthritis. Examples include 
Paget’s disease and Wilson’s disease. 
5. Congenital or Developmental: 
Abnormal anatomy such as unequal length of legs may be a cause of osteoarthritis. 
6. Genetic: 
A genetic defect may promote breakdown of the protective architecture of cartilage. 
Examples include collagen disturbances such as Ehlers- Danlos Syndrome. 
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7.  Neuropathic: 
Diseases such as Diabetes can cause nerve problems. The loss of sensation may affect 
how the body knows the position and condition of the joints or limbs. In other words, the 
body can’t tell when it is injured. 
8. Muscle dysfunction: 
Muscle dysfunction compromises the body's neuromuscular protective mechanisms, 
leading to increased joint motion and ultimately resulting in osteoarthritis. 
9. Others: 
· Nutritional problems may cause osteoarthritis.  
· Osteoporosis 
· Valgus and varus deformities of the knee. 
· Rheumatoid arthritis, infection, trauma, TB, etc. 
· Haemophilia. 
· Syringomyelia  
· Overuse of intra- articular steroid therapy. 
 It is generally observed that secondary osteoarthritis occurs in the younger age 
groups and is more severe than the primary. Apart from all the features of osteoarthritis, 
secondary osteoarthritis has the features of the corresponding aetiological condition. 
SIGNS AND SYMPTOMS: 
The disease progression of osteoarthritis (OA) is characteristically slow, occurring 
over several years or decades. The patient can become progressively less active, leading to 
morbidities related to decreasing physical activity (including potential weight gain).  
Early in the disease process of osteoarthritis, the joints may appear normal, and the 
patient’s gait may be antalgic if weight-bearing joints are involved.  
Pain: 
  Pain is the most common symptom of osteoarthritis. It is usually made worse by 
moving the joint or placing weight on it, and it is usually relieved by rest.   As the condition 
progresses and inflammation develops, pain may become constant. 
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Pain mechanisms in osteoarthritis: 
  Pain, the main Absent ing symptom of osteoarthritis, is presumed to arise from a 
combination of mechanisms, including the following:  
· Osteophytic periosteal elevation 
· Vascular congestion of subchondral bone, leading to increased intraosseous pressure 
· Synovitis with activation of synovial membrane nociceptors 
· Fatigue in muscles that cross the joint 
· Overall joint contracture 
· Joint effusion and stretching of the joint capsule  
· Torn menisci 
· Inflammation of periarticular bursae 
· Periarticular muscle spasm 
· Psychological factors 
· Crepitus (a rough or crunchy sensation) 
Stiffness: 
     Stiffness of the affected joint is often noticed first thing in the morning, and after 
resting. Stiffness during rest (gelling) may develop, with morning joint stiffness usually 
lasting for less than 30 minutes. 
Swelling: 
    Swelling, which is sometimes warm to touch, may be noticeable in an arthritic joint. 
Deformity: 
  Deformity can occur with osteoarthritis due to bone growths and cartilage loss. Bone 
growths in the end joints of the fingers are called Heberden’s nodes. Bouchard’s nodes are 
bone growths in the middle joints of the fingers. Degeneration of knee cartilage can result in 
the outward curvature of knees (bow- leggedness). 
PHYSICAL EXAMINATION: 
Physical examination findings in patients with the disease are mostly limited to the 
affected joints. A deep, achy joint pain, presumably arising from a combination of 
mechanisms, is the main Absent ing symptom of osteoarthritis. Also, reduced range of 
motion and crepitus are frequently Absent . 
Malalignment with a bony enlargement (depending on the disease’s severity) may 
occur. Most cases of osteoarthritis do not involve erythema or warmth over the affected 
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joints. However, an effusion may be Absent . Limitation of joint motion or muscle atrophy 
around a more severely affected joint may occur.  
Heberden nodes, which reAbsent  palpable osteophytes in the distal interphalangeal  
joints, are characteristic in women but not in men. Inflammatory changes are typically absent 
or at least not pronounced.  
DIAGNOSIS: 
There is no single sign, symptom or test result that allows a definitive diagnosis of 
osteoarthritis. Instead the diagnosis is based on a consideration of several factors, including 
the presence of the characteristic signs and symptoms of osteoarthritis, physical examination 
and the results of laboratory tests and x-rays. 
PROGRESSION OF OSTEOARTHRITIS: 
The etiopathogenesis of osteoarthritis has been divided into 3 stages.  
1. Proteolytic breakdown of the cartilage matrix occurs.  
2. The fibrillation and erosion of the cartilage surface, with a subsequent release of 
proteoglycan and collagen fragments into the synovial fluid.  
3.  The breakdown products of cartilage induce a chronic inflammatory response in 
the synovium.   
PROGNOSIS:  
The prognosis of osteoarthritis depends on the joints involved and the severity of the 
condition. A several clinical features associated with more rapid knee osteoarthritis (OA) 
progression, these include age, body mass index, varus deformity, and multiple involved 
joints, and their presence may help identify those more likely to have knee OA progression. 
The prognosis is good for patients with osteoarthritis who have undergone joint 
replacement, with success rates for hip and knee arthroplasty being generally more than 90%. 
However, a joint prosthesis may need revision 10-15 years after its installation, depending on 
the patient's activity level. Younger and more active patients will require revisions, whereas 
the majority of older patients will not. 
DIAGNOSTIC CRITERIA: 
Formal criteria helpful for diagnosis of osteoarthritis in synovial joints: 
· Age greater than 60 years. 
· Pain and swelling in knee joint 
· Morning stiffness lasting less than 30 minutes. 
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· Crackling sensation (crepitus) Absent  in knee joint. 
· Joint- line or periarticular tenderness.  
· Bony swelling (osteophyte) around joint margins. 
· Restricted joint movements 
INVESTIGATIONS: 
1. X-  Ray  
                 Radiological features: The earliest change seen is the asymmetrical narrowing 
of the joint space and subchondral sclerosis in the medial compartment of the joint.  Later, 
osteophytes are seen in the periphery of the articular surfaces of the femur, tibia and patella. 
2. Arthroscopic Examination 
It allows direct inspection and visualization of the damaged joint surface. 
3. Synovial fluid Analysis 
Shows  non-inflammatory picture. 
4. Bone scan , CT, MRI. 
COMPLICATIONS OF OSTEOARTHRITIS: 
The major complications of osteoarthritis of knee 
· Joint deformities 
· Subluxation  
· Ankylosis  
· Intra- articular loose bodies 
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PREPARATION AND PROPERTIES OF TRIAL DRUGS 
STANDARD OPERATING PROCEDURE FOR THE PREPARATION OF AVURI 
KARPAM (Int.)  AND VADHA NOIKKU ENNAI (Ext.)  
Source of Trial Medicine: 
           The required raw drugs for the preparation of Avuri Karpam (Internal) and Vatha 
Noikku Ennai (External) were purchased from a well reputed country shop and the raw drugs 
were authenticated in the Medicinal Botany department of NIS. Then the raw drugs were 
purified as per siddha literatures.  
AVURI KARPAM (INTERNAL MEDICINE) 
Ingredients: 
· Avuri ilai (Indicofera tinctoria)                                                      - 35gms 
· Manjal karisalai (Wedelia chinensis)                      - 35gms 
· Kuppaimeni ilai (Acalypha indica)                                           - 35gms 
·  Kottai karanthai ilai (Sphaeranthus indicus)   - 35gms                                                   
· Vellai karisalai (Eclipta alba)                                                         - 35gms 
· Vallarai (Centella asiatica)                                                        - 35gms 
· Seruppadai (Glinus lotoides)                       - 35 gms  
Method of Purification:  
Avuri: 
            Leaves are washed in pure water and dried in shadow. 
Kaiyanthagarai: 
        Leaves are washed in pure water and dried in shadow. 
 Kuppaimeni:                    
          Leaves are washed in pure water and dried in shadow. 
Kottaikaranthai:                      
          Leaves are washed in pure water and dried in shadow. 
Vallarai:                      
          Leaves are washed in pure water and dried in shadow. 
Seruppadai  
 Leaves are washed in pure water and dried in shadow. 
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Method of Preparation: 
 The purified leaves are dried in shadow. The dried leaves are pulverized by an electric 
grinder into fine powder and then it is sieved by using a fine silk cloth (Vasthirakayam). The 
fine powder is mixed with milk and then backed in a backing pan (Pittavial method). Then it 
is dried and ultra filtered by a cotton cloth and made into fine powder again. The powder is 
stored in a clean, dry air tight glass bottle. 
Drug storage:     
The trial drug is stored in clean and dry glass bottles. 
Dispensing: 
        The chooranam is given in packets. 
VADHA NOIKKU ENNAI (EXTERNAL DRUG) 
Ingredients: 
Nathaisoori ver (Spermacoce hispida )                                     - 35 gms 
Muthiyar koonthal samoolam (Cuscuta reflexa)              - 35 gms 
Vidathari ver (Dichrostachys cinerea)      - 35 gms 
Uthamani ver (Pergularia daemia)                                            - 35gms 
Vembu ver (Azadirachta indica)                                              - 35gms 
Poondu (Allium sativum)                                                         - 35gms 
Vasambu (Acorus calamus)                                                     - 35gms 
Nayuruvisamoolam (Acyranthes aspera)                                      - 35gms 
Method of preparation: 
The raw drugs were powdered into chooranam (fine powder) then the above 
choornam is prepared as karkam by adding sufficient water. Then the karkam is added with 
gingely oil and mixed well together then subjected to heat until it is brought to thailam 
consistency.       
Drug storage:     
The oil is stored in clean and dry narrow mouthed bottles. 
Dispensing: 
         Oil is given in glass bottles.    
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PROPERTIES OF TRIAL DRUGS 
INTERNAL DRUG: 
1. AVURI-«×Ã¢ ( INDIAN INDIGO PLANT) 
 Botanical name: Indigofera tinctoria, Linn.  
 Family: Fabaceae 
 Actions:  
    Germicide 
     Antiperiodic   
  Stimulant 
    Antioxidant 
  Antinociceptive 
    Hypolipidemic 
    Antiproliferative   
      Antidiabetic 
        Hepatoprotective 
         Antimicrobial 
       Anti-inflammatory 
General properties:       
“¯Ã¢ÂÄ× Ã¢ò¾¨Æò¾¡ý µÐ À¾¢¦Éñ 
«Ã¢Â¿ï¨ºò ¾¢ýÈÅ÷ìÌõ ¬Ìõ-¦¾Ã¢ÅÃ¢Â 
Å¡¾¦ÅôÒ ¸¡Á¡¨Ä ¨Áó¾÷ ÌÚÁ¡ó¾ï 
º£¾õ «¸üÚó ¦¾Ã¢’’. 
                                        -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
         Indican 
 Indirubin 
 Glycosides 
 Carbohydrates 
Saponins 
Tannin 
Flavanoides 
Phenolic compounds  
Protein ang aminoacids 
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2. MANJAL KARISALAI: Áïºû ¸Ã¢º¡¨Ä 
Botanical name: Wedelia chinensis 
Family: Astraceae 
Actions: 
Cholagogue 
            Tonic 
Alterative 
Emetic 
Purgative 
Deobstruent 
Hepatotonic 
General properties:  
“¦À¡üÈ¨Äì¨¸ Â¡ó¾¸¨Ã ¦À¡ýÉ¢ÈÁ¡ì ÌõÓ¼¨Ä 
    Íò¾ ÓÈì¸ðÌî Í¸í¦¸¡ÎìÌï - º¢üÈ¢¨¼Â¡ö 
    º¢óàÃí ¸ð¸¡Ìï º¢ó¨¾ ¾¨ÉòÐÄìÌõ 
 ¯ó¾¢ÅÇ÷ ÌýÁ¦Á¡Æ¢ì Ìõ”. 
                                    -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Wedecolacton 
B-amyrin 
3. VELLAI KARISALAI: ¦Åû¨Çì ¸Ã¢º¡¨Ä 
Botanical name: Eclipta alba 
Family: Astraceae 
Actions: 
Alterative 
Purgative 
Deobstruent 
Hepatotonic 
Antioxidant 
Antihyperglycemic 
Analgesic 
Antihyperlipidemic 
Immunomodulatory 
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 General properties: 
“ÌÃü¸õÁü ¸¡Á¡¨Ä Ìð¼¦Á¡Î §º¡¨À 
ÔÈüÀ¡ñÎ Àý§É¡ ¦Â¡Æ¢Â-¿¢Ãü¦º¡ýÉ 
¦ÁöÂ¡ó ¾¸¨Ã¦Â¡ò¾ Á£Ç¢ ñÏ ¿üÒÄòÐì 
¨¸Â¡ó ¾¸¨Ã¦Â¡ò¾ì ¸¡ø”. 
                                        -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
 Flavonoides 
Stigmasterol 
a-terthienylmethanol 
wedelolactone 
demethyl wedelolactone 
4. KUPPAI MENI: Ìô¨À§ÁÉ¢ 
Botanical name: Acalypha indica. Linn 
Family:  Euphorbiaceae 
Actions: 
Anodyne 
Anthelmintic 
Cathartic 
Diuretic 
Emetic 
Expectorant 
Emmenagogue 
General properties: 
“¾ó¾ã ÄôÀ¢½¢¾£ó ¾ó¾¢ÎÒñ º÷ÅÅ¢¼õ 
 ¯óÐÌýÁõ Å¡¾õ ¯¾¢Ãã-Äó¾¢É× 
 ÝÄïÍ Å¡ºõ ¦¾¡¼÷À£ ºí¸Àõ§À¡õ 
 »¡Äí¦¸¡û §ÁÉ¢Â¾ É¡ø”. 
       -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Acalypus 
Acalypine 
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Triacetonamine 
Hydrocyanic acid 
Stygmasterol 
Acalyphamide 
Kaemferol glycoside 
Tannin 
Beta sitosterol 
Succinamide 
Mauritianin 
5. KOTTAI KARANTHAI: ¦¸¡ð¨¼ì ¸Ãó¨¾  
Botanical name: Sphaeranthus indicus 
Family: Astraceae 
Actions: 
Alterative 
Demulcent 
Depurative 
Refrigerant 
Tonic 
General properties:  
“¦¸¡ð¨¼ì ¸Ãó¨¾¾¨Éì Üº¡ÁÖñ¼Å÷ìÌ 
¦Åð¨¼ ¾½¢ÔÁ¾¢ §Á¸õ§À¡ó - Ðð¼î 
¦º¡È¢ º¢ÃíÌ Åý¸ÃôÀ¡ý §È¡üÈ¡Ð ¿¡Ùõ 
ÁÈ¢ÁÄÓó ¾¡É¢ÈíÌ Á¡ø”. 
                                        -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Methyl charicol 
a-Terpinine 
literal 
a-ionone 
p  methoxy cinnamaldehyde 
tannin 
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6. VALLARAI: ÅøÄ¡¨Ã  
Botanical name: Centella asiatica 
Family: Apiaceae 
Actions: 
Alterative 
Tonic 
Diuretic 
Stimulant 
Emmenagogue 
General properties: 
“«ì¸Ã §¿¡ö Á¡Úõ «¸Öõ ÅÂ¢üÈ¢Æ¢× 
¾ì¸Å¢Ãò ¾ì¸ÎôÒ ¾¡§ÉÌõ - Àì¸ò¾¢ø 
±øÄ¡¨Ã ÔÁÕó¦¾ý §ÈÔ¨ÃòÐ ¿ýÁ¨ÉÔû 
ÅøÄ¡¨Ã ¨ÂÅÇ÷òÐ ¨Å”. 
                                      -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Triterphenoid 
Asiaticoside A &B 
Sitosterol 
Vallarine 
Pectic acid 
Tannin 
Bramoside 
7.  SERUPPADAI : ¦ºÕôÀ¨¼ 
Botanical name:  Glinus lotoides 
Family:  Molluginaceae 
Actions: 
Stimulant 
General properties: 
“¦ºÕôÀ¨¼ìÌ Å¡¾Áó¾ï §º÷Å¡É §Á¸õ 
þÕôÀÊ¦¸¡û ¦À¡øÄ¡ þº¢×õ - Å¢ÚôÀÊìÌï 
Ý¨Ä¦Â¡Î Å¡¾ÌýÁó §¾¡üÈ¡ ¦¾¡Õ¿¡Ùõ 
§Å¨Ä¦Â¡ò¾ ¸ñ½¡ö Å¢ÇõÒ”. 
                                      -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
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Chemical constituents: 
Flavone-c-glycoside orientin 
Vitexin 
Reducing sugar 
EXTERNAL DRUG: 
1. NATHAI CHURI : ¿ò¨¾ÝÃ¢ 
Botanical name: Spermacoce hispida 
Family: Rubiaceae 
Actions: 
Alterative 
Tonic 
General properties: 
Å¢¨¾Â¢É¡ø ¦ÀÕí¸Æ¢îºø, º£¾§À¾¢ ¿£íÌõ. §Å÷ ¯¼¨Äò §¾üÚõ. 
Chemical constituents: 
Borreline 
Ursolic acid 
Beta sitosterol 
Isorhamnetin 
2. MUTHIYAR KOONTHAL : Ó¾¢Â¡÷ Üó¾ø 
Botanical name: Cuscuta reflexa 
Family:  Convolvulaceae 
Actions: 
Astringent 
Alterative 
Stomachic 
General properties: 
“¸ÎôÒ ¸Æ¢îºø ¸½ýÈÍÃ ¾¡¸õ 
  þÎôÒÅÄ¢ Å¡¾ Á¢Åü§È¡ - ¼ÎôÀ 
  Å¢¾¢¨ÃÅ¡ ¦ÅýÈ¨ÆìÌ §Á¸Óõ §À¡Ìõ 
  Ì¾¢¨Ã Å¡Ä¢ìÌì Ì¨ÄóÐ”. 
                                             -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
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Chemical constituents: 
Cuscutin 
Flavanoides 
Resin 
Quercetin 
3. VIDATHAARI: Å¢¼¾¡Ã¢ 
Botanical name: Dichrostachys cinerea 
Family: miosaceae 
Actions:  
Astringent 
Stimulant 
Tonic 
General properties: 
“Ó¨Ç¨ÂÅÕ Å¢ì¸¢ýÈ ãÄ§Ã¡ ¸ò¨¾ 
  Â¨ÇÔÓ¾¢ Ãò¨¾ Â¼í¸¡ - Ð¨Ç¾¡¸ 
  §Å¸ò¨¾ô §À¡ì¸¢Å¢Îõ ¦ÅöÂÅ¢¼ò §¾ºì¸¢Ã 
  Å¡¸ò¨¾ì ¸¡öÓ¨ÄÂ¡ö Å¡úòÐ”. 
                                       -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Chemical constituents: 
Fatty acid 
Linoleic acid 
Palmitic acid 
Nitrogen 
Leucin 
4. UTHAAMANI: ¯ò¾¡Á½¢ 
Botanical name:  Pergularia daemia 
Family: Asclepiadaceae  
Actions: 
Expectorant 
Anthelmintic 
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Emetic 
General properties: 
“¬Ä¢ò ¦¾Øó¾§¿¡ö «ò¾¨É Ôó¾£Õ§Á 
§ÅÄ¢ô ÀÕò¾¢Â¾¢ý ¦Áøþ¨ÄÂ¡ø - §Å¦Ä¡òÐì 
¸ñÊìÌõ Å¡¾í ¸ÎïºýÉ¢ §¾¡¼Óõ§À¡õ 
¯ñÊìÌõ Å¡º¨ÉÂ¡õ µÐ”. 
                                            -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Alpha amyrin 
Beta amyrin 
Beta sitosterol 
5. VEMBU : §ÅõÒ 
Botanical name: Azadirachta indica 
Family: meliaceae 
Actions: 
Stimulant 
Anthelmintic 
Discutient 
General properties: 
“Òó¾¢Â¢¨¾ò ¾£ðÎÅ¢ìÌõ ÒýÀ¢½¢¨Â §Â¡ðÎÅ¢ìÌ 
Á¢ó¾¢Âò¨¾ ¿ýÈ¡ Â¢¨ºÅ¢ìÌõ - ºó¾¾Áõ 
Å£Úñ¼¡í ¸üÀ Á¢¸×ñ¼¡ ¦Áï»¡ýÚõ 
Á¡ÈýÈ¡ ¨ÃÂÁ¢øÄ¡ Áø”. 
                                            -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Azadiractin A,B,D,H 
Nimbinin 
Nimbidine 
Nimbione 
Nimbinone 
Geducin 
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6. POONDU : âñÎ 
Botanical name: Allium sativam 
Family: Liliaceae 
Actions: 
Carminative 
Stomachic 
Tonic 
Alterative 
Stimulant 
Expectorant 
Diuretic 
Anthelmintic 
General properties:  
“ºýÉ¢¦Â¡Î Å¡¾ó ¾¨Ä§¿¡× ¾¡ûÅÄ¢ 
ÁýÉ¢ÅÕ ¿£÷ì§¸¡¨Å Åýº£¾õ - «ýÉ§Á 
¯ûÙûÇ¢ ¸ñÀ¡ö ¯¨ÇãÄ §Ã¡¸Óõ §À¡õ 
¦ÅûÙûÇ¢ ¾ýÉ¡ø ¦ÅÕñÎ”. 
                                            -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Allicin 
Essential oil 
Fattyacids 
Alkylcystines 
Sulphur 
Vitamins 
Acrid volatileoil 
Starch 
7. VASAMBU: ÅºõÒ 
Botanical name: Acorus calamus 
Family: Araceae 
Actions: 
Stimulant 
Stomachic 
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Anti periodic 
Emetic 
Disinfectant 
Germicide 
General properties: 
“À¡õÀ¡¾¢ ¿ïºü Ò¾ôÒñ ÅÄ¢Å¢¼À¡¸í ÌýÁõ 
ÝõÀ¡ Ã¢Ãò¾À¢ò ¾õÓ¸ ¿¡üÈõÅý Ý¨ÄºýÉ¢ 
Å£õÀ¡õ¨À ¸¡ºõ À¢Ä£¸ï º¢Ä¢À¾õ Å£È¢ÕÁø 
¾¡õÀ¡í ¸¢ÕÁ¢ Â¢¨Å¦ÂÌ Á¡º¢Å ºõÀ¢¨É§Â”. 
                                            -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Chemical constituents: 
Acorin 
Palmitic acid 
Eugenol 
Acoretin 
Calamine 
Camphene 
8. NAAYURUVI SAMOOLAM : ¿¡ÔÕÅ¢ 
Botanical name: Achyranthes aspera  
Family: Amaranthaceae 
Actions: 
Astringent 
Diuretic 
Alterative 
Anti periodic 
General properties: 
“ÁÄ¢¸¡Ãí ¨¸ôÒûÇ «ÀÁ¡÷ì¸¢ Â¢ý§ÅÃ¡ø Åº¢Â Óñ¼¡õ 
þ¨Ä ãÄ ¯¾¢ÃÁó¾õ §À¾¢¸Àõ Å¢Â÷×¾ó¾¢ Â¢ÈíÌ §Á¸õ 
Á¨Ä§ÂÚõ ÀÊÒÃ¢Ô ÓûÇÃ¢º¢ Àº¢Á¡üÚõ ÅÉº ãÄõ 
ÀÄÁ¡¾÷ì ÌûÇØì¨¸ ¿£ìÌÅí¸î º¢óàÃõ ÀñÏÁ¡§¾¡”. 
                                            -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
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Chemical constituents: 
Achyranthine 
Triterphenoid 
Saponins 
Aglycone 
Oleanolic acid 
Insect moulting hormone 
9. ¿ø¦Äñ¦½ö – GINGELLY OIL 
Botanical name:  Sesamum indicum, Linn. 
Family:  Pedaliaceae 
General properties: 
"Òò¾¢¿ÂÉìÌÇ¢÷îº¢ âÃ¢ôÒ ¦ÁöôÒÇ¸ï 
  ºòÐÅí ¸ó¾¢ ¾É¢Â¢Ç¨Á - ¦Áò¾×ñ¼¡í 
  ¸ñ§½¡ö ¦ºÅ¢§¿¡ö ¸À¡ÄÅÆø ¸¡º§¿¡ö 
  Òñ§½¡ö§À¡ ¦Áñ¦½öÂ¡ü §À¡üÚ". 
                                               - «¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
Actions: 
Demulcent 
Laxative  
Nutritive 
Emollient 
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 INGREDIENTS OF INTERNAL MEDICINE(AVURI KARPAM) 
               
  AVURI                                                       VELLAI KARISALAI 
         
 
 
 
               MANJAL KARISALAI                                       KUPPAIMENI 
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KOTTAI KARANTHAI                                          VALLARAI 
            
 
SERUPPADAI 
 
 
 
INGREDIENTS OF EXTERNAL MEDICINE(VATHA NOIKKU ENNAI) 
              NATHAISORI     MUTHIYARKONTHAL 
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   VIDATHARI   UTHAMANI 
                    
 
              VEMBU         POONDU 
                     
 
            
 
 VASAMBU               NAYURUVI 
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AVURI KARPAM 
 
 
 
 
VATHA NOIKKU ENNAI 
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VARMAM 
Varmam   is a science dealing with the impact to innumerable nerve junctions of the 
human body.  The changes occurring in the body on being hit at some specific points on the 
body directly or indirectly with a particular force is known as varmam. 
Synonyms of Varmam: 
 Kalam, adakkam, marmam, sutcham, vanmam, emam, idu , karuvi, kalai, sarvaathma 
vazhum veedu, seevan swasam, maaigai, poruthu odivu etc..   
Varmam – Art as well as science: 
 Varmam is an art as well as a science.  As an art it can be employed to attack a person 
to disable him (which is normally not done) and as a science, it helps treat persons from the 
impact arising from traumatic injuries. 
Varmam and other Martial arts: 
 Varmam has also many similarities to other martial arts such as silambam, sword 
fighting, kalari etc.  In these arts, the life energy centers of men are made known to 
practitioners to enable them to achieve their ends. 
Signs of life energy centers if affected: 
 Hundreds of life energy centers of human body lie dormant as bones, nerves, veins, 
muscles, joints and inner organs are found either deep or at the surface of the body.  Vital life 
centers are dominant on bones and joints.  Medium life centre on nerves.  Inner life centers 
on muscles.  
If the life energy centers are traumatized by hit or cut either directly or indirectly, and 
then whole body is left out of control.  In other words the whole body is paralyzed.  It is 
manifested by symptoms like fainting, sprain, swelling, bleeding, shivering, fractures, 
dislocations or even death. 
Varmam points to be manipulated in Azhal Keel Vayu patients: 
· Kaal Moottu Varmam  
· Komberi 
· Viruthi 
· Ullangal vellai                                                       
· Kutri Varmam       
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KAAL MOOTTU VARMAM: 
Synonyms: 
   ÓðÎ Å÷Áõ (Å÷Á Íò¾¢Ãõ-101)  
ãðÎ Å÷Áõ (¸ñ½¡Ê- 500 ) 
¸¡øãðÎ Å÷Áõ (Å÷Á Å¢ÃÄÇ× áø) 
Location: 
   ¾¡É¾¢§Ä ÓðÊ¨ºÅ¢ø ãðÎ Å÷Áõ (Å÷Á ¸ñ½¡Ê-500) 
             Located in the popliteal fossa. 
KOMBERI VARMAM: 
Synonyms: 
   ÐõÀ¢ì¸¡Ä Å÷Áõ (Å÷Á áÄÇ× áø) 
   ¦¸¡õ§ÀÈ¢ Å÷Áõ (Å÷Á Ýò¾¢Ãõ 101) 
Location: 
   ²Ìõ Ó¼× þ¨ÈÃñÊø ÐõÀ¢ì¸¡Äõ («ÊÅ÷Á Ýðºõ - 500) 
      Located at the centre of the medial aspect of the leg. 
VIRUTHI VARMAM: 
Synonyms: 
   Å¢ü¾¢ Å÷Áõ (Å÷Á ¸ñ½¡Ê-500)  
   Å¢÷ò¾¢ Å÷Áõ («ÊÅ÷Á Ýðºõ-500)  
   Å¢Õò¾¢ Å÷Áõ (Å÷Á Ä¡¼ Ýò¾¢Ãõ-300) 
Location: 
   §À¡¦ÁýÈ ¦ÀÕÅ¢Ãø ¦Á¡Æ¢ §Áø Å¢÷ò¾ ¸¡Äõ («ÊÅ÷Á Ýðºõ–500) 
      Located in the space in between the great toe and second toe on the dorsum of the 
foot. 
ULLANGAL VELLAI VARMAM: 
Synonyms: 
   ¦Åû¨Ç Å÷Áõ (Å÷Á ´Ê×ÓÈ¢× ºÃÝò¾¢Ãõ-1200) 
   «¼í¸ø Å÷Áõ (Å÷Á Ýò¾¢Ãõ 101) 
   ¸¡ø ¦Åû¨Ç Å÷Áõ («ÊÅ÷Á Ýðºõ–500)  
   ¯ûÇí¸¡ø Å÷Áõ (Å÷Á Å¢ÃÄÇ× áø) 
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Location: 
   «¸Á¡É ¯ûÇõ ¸¡ø ¦Åû¨Ç Å÷Áõ («ÊÅ÷Á Ýðºõ–500) 
       Located on the depression in between the eminences of great toe and second  
toe in the plantar aspect of the foot                 
KUTRI VARMAM : 
Synonyms: 
   ÌüÈ¢ì Å÷Áõ (Å÷Á º¡Ã¢ - 205)  
   Ìò¾¢ì ¸¡Äõ (Å÷Á ¸ñ½¡Ê – 500) 
Location: 
Óý§É ¦º¡ýÉ ¦ºÅ¢ìÌò¾¢ì ¸¢ÕÅ¢ÃÄ¢ø 
     Óì¸¢ÂÁ¡õ ÌüÈ¢Å÷Áõ Ãñ¼¾¡Ìõ (Å÷Á ´Ê×ÓÈ¢× ºÃÝò¾¢Ãõ-1200) 
      Located in the tragus of the ear. 
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MATERIALS AND METHODS 
The study on Azhal keel vayu was carried out in the In-Patient and Out-Patient 
Department of Sirappu Maruthuvam in Ayothidoss Pandhithar Hospital, National institute of 
Siddha, Chennai - 47. 
The disease “Azhal keel vayu” has been dealt in the Siddha Pothu Maruthuvam as one 
among the types of Keel vayu.  Patients were selected according to the clinical features as 
mentioned in Azhal keel vayu. 
Study design and conduct of study: 
Study type:   
A Pilot study 
Sample: 
Patients of Azhal keel vayu reporting at Out-Patient ward, Department of Sirappu 
Matuthuvam, Ayothidoss Pandithar Hospital of National Institute of Siddha, Tambaram 
Sanatorium, Chennai-47. 
Sample size:  
40 patients [20 OP + 20 IP]  
Out of 20 IP patients - 10 with trial medicine and 10 with Varmam along with trial 
medicine. 
Study place:  
Out-Patient and In-Patient ward, Department of Sirappu Maruthuvam, Ayothidoss 
Pandithar Hospital, National Institute of Siddha, Tambaram sanatorium, Chennai-47. 
Study period: 
12 months  
TREATMENT: 
Internal medicine:  
Avuri karpam: 
Reference:   Pathartha Guna Vilakkam; Pg no: 43 
Dosage:  Thirigadi (1gm ) (twice a day)     
Adjuvant:   Honey 
              Duration:   48 days 
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External medicine: 
Vadha Noikku Ennai: 
Reference:  Theraiyar vagadam; Pg no: 64 
Dosage:  Q.S (for external application) 
STANDARD OPERATING PROCEDURE:  
Source of trial medicine: 
The required raw drugs for the preparation of Avuri Karpam (Internal) and Vadha 
Noikku Ennai (External) were  purchased from a well reputed country shop and the raw drugs 
were authenticated in the Medicinal Botany department of NIS. Then the raw drugs were 
purified as per siddha literatures.  
Drug storage:     
The trial drug Avuri Karpam is stored in clean and dry glass bottles and Vadha 
Niokku Ennai is stored in clean and dry narrow mouthed bottles. 
Dispensing: 
        The chooranam is given in packets and oil is given in glass bottles. 
VARMAM POINTS TO BE USED: 
· Kaal Mootu Varmam (Varma Viralalavu Nool) 
· Komberi (Varma soothiram 101) 
· Viruthi (Varma laada soothiram 300) 
· Ullangal Vellai(Adivarma sootcham 500)            
SUBJECT SELECTION: 
             Patients reporting with symptoms of Azhal Keel Vayu will be subjected to screening 
using screening Proforma. Then they will be allowed for the study fulfilling the following 
criteria: 
INCLUSION CRITERIA: 
· Age : 30-65 Yrs 
· Sex : Both male and female 
· Patients having symptoms of arthritis of both knee joints, Pain, swelling, stiffness, 
crepitations, restricted movements of both knee joints. 
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· Patients who are willing to undergo radiological investigation, Laboratory 
investigations. 
· Patients willing to sign the informed consent stating that he/she will conscientiously  
stick to the treatment during 48days but can opt out of the trial of his/her own 
conscious discretion. 
· Willing to co operate to take photographs whenever required with his/her consent.  
EXCLUSION CRITERIA: 
· Cardiac diseases 
· Hypertension 
· Rheumatoid arthritis 
· Use of Narcotics 
· Pregnancy and lactation 
· History of trauma 
· Patient with any other serious systemic illness 
WITHDRAWAL CRITERIA: 
· Intolerance to the drug and development of adverse reactions during drug trial. 
· Poor patient compliance and defaulters. 
· Patient turning unwilling to continue in the course of clinical trial. 
· Occurrence of any serious illness 
TESTS AND ASSESSMENTS: 
· Clinical assessment  
· Laboratory investigations 
· Radiological investigations 
· Siddha system assessment 
A.CLINICAL ASSESSMENT: 
· Pain  
· Swelling  
· Stiffness  
· Crepitations 
· Tenderness 
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· Warmth 
· Restricted movements  
OUTCOME: 
Outcome of the study will be assessed by the following:  
      1. Universal Pain assessment scale 
      2. Restricted movement assessment scale 
1. UNIVERSAL PAIN ASSESMENT SCALE:1 
 
              Grade   0    : No Pain 
                Grade  1 -3 :  Mild pain 
                 Grade  4-6 :  Moderate pain 
                      Grade  7-10 :  Severe pain     
2. RESTRICTED MOVEMENT ASSESSMENT SCALE:                
Gradation of movements: 
Grade 1 - Fit for all activities, do their work without support. 
Grade II - Mild pain Absent  in knee joint, mild restricted movements. 
Grade III - Pain Absent  in knee joint, moderate restriction of movements. 
Grade IV - Severe pain, bed ridden. 
(Reference: Clinical manual for nursing practice (National Institute of Health Warren Grant 
Magnuson Clinical Centre) 
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B. Routine investigation 
Blood: 
· Hb 
· Total WBC Count 
§ DC  :            
o Polymorphs 
o Lymphocytes  
o Eosinophils  
o Basophils Monocytes  
 
· Total RBC count 
· ESR 
½ Hr:                 1 Hr: 
· Blood sugar 
Fasting:               PP: 
Urine: 
· Albumin 
· Sugar 
· Deposits 
Renal function tests: 
· Urea 
· Creatinine 
Liver function tests: 
· Serum total bilirubin 
· Direct bilirubin 
· Indirect bilirubin 
· Serum Alkaline phosphotases 
· SGOT 
· SGPT 
C. RADIOLOGICAL INVESTIGATIONS 
      X- Ray Knee joints (AP and Lat view) 
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SPECIFIC INVESTIGATIONS: 
· CRP 
· ASO TITRE 
· RA FACTOR 
D. SIDDHA PARAMETERS: 
Envagai thervugal: 
· Naadi 
· Sparisam 
· Naa 
· Niram 
· Mozhi 
· Vizhi 
· Malam 
· Moothiram 
· NeerkKuri 
· Neikkuri 
DATA COLLECTION FORMS: 
Required information will be collected from each patient by using the following 
forms: 
FORMS: 
FORM I : Screening and Selection Proforma 
FORM II : History taking Proforma  
FORM III : Clinical assessment Proforma 
FORM IV : Laboratory Investigation Proforma 
FORM V : Informed Consent Form 
FORM VI : Withdrawal Form 
FORM VII  : Patient information sheet 
FORM VIII : Dietary Advice form 
FORM IX : Adverse Reaction form 
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METHODOLOGY: 
 
PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA 
EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
INFORMED CONSENT FORM 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMACOLOGICAL 
ASSESSMENT 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
WITH 
VARAMAM 
WITHOUT 
VARAMAM 
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STUDY ENROLLMENT:  
Patients reporting at the OPD with the clinical symptoms of Azhal Keel Vayu will be 
examined clinically for enrolling in the study based on the inclusion and exclusion criteria.  
The patients who were enrolled would be informed (Form VI) about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and informed consent would be obtained in writing from them in the 
consent form (Form VI).  
All these patients will be given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone number etc. 
will be given, so as to report easily should any complications arises. 
Complete clinical history, complaints and duration, examination findings and 
laboratory investigations -- would be recorded in the prescribed Proforma. 
 Patients will be advised to take the trial drug and to follow the appropriate dietary 
advice. 
CONDUCT OF THE STUDY: 
Purgation with Agasthiyar kuzhambu 130mg with ginger juice at early morning in 
empty stomach will be given for balancing the deranged mukkutram a day before the 
treatment.  
The trial drug Avuri Karpam, Internally and Vadha Noikku Ennai Externally are 
given continuously for 48 days.  OP patients are requested to visit the hospital once in seven 
days.  In each and every visit clinical assessment is done and prognosis is noted in the 
Prescribed Proformas.  For In patients clinical assessment is done daily. 10 IP patients will be 
given Varmam treatment along with trial medicines. Laboratory investigations and 
Radiological investigation are done on the First day and the last day of the trial.  Defaulters of 
will not be allowed to continue and be withdrawn from the study.  
DATA ANALYSIS: 
 After enrolling the patient for the study, a separate file for each patient will be opened 
and all forms will be kept in the file.  Study No. and Patient No. will be written on the top of 
file for easy identification.  Whenever the patient visits OPD during the study period, the 
respective patient’s file will be taken and necessary entries will be made at the assessment 
form or other suitable form.  The screening forms will be filed separately.  The data 
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recordings will be monitored for completion and adverse event by HOD and 
pharmacovigilance committee.  All forms will be further scrutinized in presence of 
Investigators by Sr. Research Officer (Statistics) for logical errors and incompleteness of data 
to avoid any bias.  No modification in the results is permitted for unbiased report. 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National Institute 
of Siddha and the same will be informed to the Pharmaco-vigilance committee of NIS. 
ETHICAL ISSUES: 
· To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of laboratory 
equipments will be used.      
· No other external or internal medicines will be used, other than the trial drug for 
osteoarthritis. There will be no infringement on the rights of the patient. 
· The data collected from the patient will be kept confidential.  
· After getting the consent of the patient only (through consent form in their own 
vernacular language) they will be enrolled in the study. 
· Treatment would be provided free of cost. 
· In any adverse reaction observed during the trial the patients will be given alternative 
treatment at National Institute of Siddha for further management.  
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OBSERVATION AND RESULTS 
 
1.  Gender distribution 
2.  Age Distribution 
3.  Kaalam distribution 
4.  Occupational Status 
5.  Seasonal variations 
6.  Thinai 
7.  Socio-economic Status 
8. Dietary Habits 
9.  Precipitating Factors 
10. Distribution of Mukkutram 
11. Udal Kattugal 
12. Ennvagai Thervugal 
13. Neerkkuri Neikkuri 
14. Naadi 
15. Disturbances in Kanmenthiriyam 
16. Duration of illness 
17. Involvement of knee joints 
18. Clinical features 
19. Results after treatment 
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1. GENDER DISTRIBUTION: 
GENDER NUMBER OF CASES PERRCENTAGE (%) 
MALE 13 32.50 
FEMALE 27 67.50 
TOTAL 40 100  
 
 
Inference:  
                  Among 40 cases, the disease was found to be higher in Female i.e. (67.50 %). 
 
2. AGE DISTRIBUTION: 
AGE (YEAR) NUMBER OF CASES PERCENTAGE% 
31-40 07 17.50 
41-50 16 40.00 
51-60 13 32.50 
61-65 04 10.00 
TOTAL 40 100 
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Inference:  
Among 40 cases, the disease was found to be higher in the age group 41-50 years. 
3. KAALAM DISTRIBUTION: 
Vaatha Kaalam   - 3 cases (7.50%)  
Pitha Kaalam    - 37 cases (92.5%)  
Kaba Kaalam   - no cases (0%) 
 
Inference:  
Out of 40 cases,   37 cases were found to be in Pitha kaalam, i.e. between 
33 – 66 years and 3 cases were found to be in Vaatha kaalam (31-32 years). 
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4. OCCUPATIONAL STATUS: 
OCCUPATION NUMBER OF CASES PERCENTAGE (%) 
COOLIE 15 25 
SECTION OFFICER 1 2.5 
BUS CONDUCTOR 1 2.5 
HOME MAKER 21 52.5 
TYPIST 1 2.5 
ASST. MANAGER 1 2.5 
TOTAL 40 100 
 
 
 
Inference:    
Out of 40 cases, 21 patients (52.5 %) were Home makers. 
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4. SEASONAL VARIATIONS: 
 
SEASON NUMBER OF CASES PERCENTAGE (%) 
KAAR KAALAM 9 22.5 
KOOTHIR KAALAM - - 
MUNPANI KAALAM - - 
PINPANI KAALAM - - 
ELAVENIL KAALAM - - 
MUTHUVENIL KAALAM 31 77.5 
TOTAL 40 100 
 
 
 
Inference:  
           Out of 40 cases, 9 patients (22.5%) were admitted in Kaar Kaalam and 31 patients 
(77.5%) were admitted in Muthuvenil Kaalam. 
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5. THINAI: 
 
THINAI NUMBER OF CASES PERCENTAGE (%) 
KURINJI - - 
MULLAI - - 
MARUTHAM 5 12.5 
NEITHAL 35 87.5 
PAALAI - - 
TOTAL 40 100 
 
 
 
Inference: 
 Among the 40 patients, 5 patients (12.5 %) were from Marutham and 35 patients      
(87.5 %) were from Neithal thinai. 
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6. SOCIO- ECONOMIC STATUS: 
 
SOCIO- ECONOMIC STATUS NUMBER OF CASES PERCENTAGE (%) 
HIGHER INCOME  3 7.5 
MIDDLE INCOME  6 15 
LOWER INCOME  31 77.5 
TOTAL 40 100 
 
 
 
 
Inference: 
Out of 40 cases 7.5% cases from upper and 15% cases were from middle class and 
77.5% from lower class. 
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7. DIETARY HABITS (D.H.): 
 
D.H. NUMBER OF CASES PERCENTAGE% 
VEGETARIAN 7 17.5 
NON-VEGETARIAN 33 82.5 
TOTAL 40 100 
 
 
 
 
Inference: 
Out of 40 cases 82.5% of cases were Non-vegetarians and 17.5% of cases were 
Vegetarians. 
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8. PRECIPITATING FACTORS: 
 
PRECIPITATING 
FACTORS 
NUMBER OF CASES PERCENTAGE% 
OBESITY 14 42.5 
OBESITY WITH 
MENOPAUSE 
12 20 
OCCUPATION RELATED 14 37.5 
H/O TRAUMA - - 
TOTAL 40 100 
 
 
Inference: 
Out of 40 cases 42.5% of cases were Obesity. 
10. DISTRIBUTION OF MUKKUTRAM: 
a. VAATHAM: 
Out of 40 cases Viyanan and Samanan were affected in all the 40 patients (100%).  
b. PITHAM: 
Out of 40 cases saathagam was affected in almost all the 40 cases (100%).  
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
OBESITY
OBESITY WITH 
MENOPAUSE OCCUPATION 
RELATED H/O TRAUMA
42.50%
20.00%
37.50%
0.00%
Pe
rc
en
ta
ge
Factors
PRECIPITATING FACTORS
 
 
70 
 
c. KABAM: 
Out of 40 cases Santhigam was affected in almost all the 40 cases (100%).  
11. UDAL THATHUKKAL: 
The Seven thathukkal which constitute our body structure and help to maintain the 
normal physiological functions get changed in Pathological conditions. 
Among the 7 Udal Kattugal, Saaram  , kozhuppu  and  Enbu were affected in all the 
40 cases (100%).   
 12. ENVAGAI THERVUGAL: 
In Siddha system of Medicine, the eight types of investigative procedure were 
adopted for clinical approach and diagnosis. The investigations were done properly and 
observations were tabulated. 
            Among the 40 cases Sparism was affected in 40 cases. 
13. NEERKKURI 
NIRAM NUMBER OF CASES PERCENTAGE% 
YELLOW 14 35 
PALE YELLOW 26 65 
DARK YELLOW - - 
 
 
Inference: 
Out of 40 cases, in 65% of cases urine was pale yellow in colour. 
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NEIKKURI: 
NEIKKURI NUMBER OF CASES PERCENTAGE% 
VAATHAM 29 72.5 
PITHAM 7 17.5 
KABAM 4 10 
TOTAL 40 100 
 
 
 
 
 
Inference: 
Out of 40 cases, in 72.5% of cases Neikkuri was found as Vaatham. 
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4. NAADI: 
NAADI NUMBER OF CASES PERCENTAGE% 
VAATHA PITHAM 30 75 
VAATHA KABAM - - 
PITHA VAATHAM 6 15 
PITHA KABAM 3 7.5 
KABA VAATHAM 1 2.5 
KABA PITHAM - - 
TOTAL 40 100 
 
 
 
 
Inference: 
Among 40 cases, vaathapitham naadi was found in 30 patients, 6 were found in 
Pithavaatham. 
 
15. DISTURBANCES IN KANMENTHIRIYAM: 
Kaal was affected in all the 40 cases (100 %) 
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16. DURATION OF ILLNESS: 
 
DURATION OF ILLNESS NUMBER OF CASES PERCENTAGE% 
6 MONTHS – 1 YEAR 8 20 
1 – 2 YEARS 15 37.5 
2 – 3 YEARS 9 22.5 
3 – 4 YEARS 1 2.5 
4 – 5 YEARS 2 5 
ABOVE 5 YEARS 5 12.5 
TOTAL 40 100 
 
 
 
 
 
  
0.00%
10.00%
20.00%
30.00%
40.00%
6 
Months-1 
Yr
1-2 Yr 2-3 Yr 3-4 Yr 4-5 Yr Above 5 
Yr
20.00%
37.50%
22.5%
2.50% 5.00%
12.50%Pe
rc
en
ta
ge
Duration
DURATION OF ILLNESS
 
 
74 
 
17. INVOLVEMENT OF KNEE JOINTS: 
 
KNEE JOINTS NUMBER OF CASES PERCENTAGE% 
BOTH KNEE JOINTS 37 92.5 
SINGLE KNEE JOINT ONLY 3 7.5 
TOTAL 40 100 
 
 
 
 
 
Inference: 
Out of 40 cases both knee joints were affected in 37 patients (92.5%).  
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18. CLINICAL FEATURES – BEFORE TREATMENT: 
CLINICAL FEATURES NO. OF CASES PERCENTAGE% 
PAIN 40 100 
SWELLING 12 30 
WARMTH 15 37.5 
TENDERNESS 32 80 
MORNING STIFFNESS 10 25 
CREPITATION 39 97.5 
DEFORMITY 3 7.5 
RESTRICTED MOVEMENTS 40 100 
 
   
 
Inference: 
Out of 40 cases, Pain and Restriction of movement Absent  in all 40 cases. 
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19. RESULTS - AFTER TREATMENT: 
RESULT NUMBER OF CASES PERCENTAGE% 
GOOD IMPROVEMENT 28 70 
MODERATE 
IMPROVEMENT 
9 22.5 
MILD IMPROVEMENT 3 7.5 
TOTAL 40 100 
 
 
 
 
 
Inference: 
Out of 40 cases, good improvement was observed in 28 patients, moderate 
improvement in 9 patients, and mild improvement in 3 patients.  
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1. UNIVERSAL PAIN ASSESMENT SCALE:       
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSAL PAIN ASSESMENT SCALE:       
               A.    0   : No Pain 
               B. 1 -3   :  Mild pain 
               C. 4-6   :  Moderate pain 
               D.7-10  :  Severe pain 
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Results of varmam manipulation according to pain scale 
 
S. 
No 
IP No Name 
Age/ 
Sex 
Pain score 
Before 
treatment 
After treatment 
1. 4941 Gnanam 
31/M 6 0 
2. 3993 Rajeshwari 
54/F 5 0 
3. 4999 Jagadeesan 
47/M 2 2 
4. 4994 Meghanadhan 
51/M 9 2 
5. 5002 Yettiyappan 
57/M 6 3 
6. 4048 Leelavathi 
48/F 9 2 
7. 5010 Ramesh 
55/M 9 2 
8. 4052 Kavitha 
34/F 8 5 
9. 4092 Elizabeth Mary 
47/F 6 0 
10. 4107 Sasikala 
44/F 6 1 
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OP AND IP CASES CLINICAL IMPROVEMENT 
Sl. OP & IP NO NAME AGE SEX DOA DOI DOD 
DAY
S RESULT 
1 C81369 Gnanam 31 M 21.07.12 08 Months 09.09.12 48 GOOD 
2 C78848 Rajeshwari 54 F 23.07.12 03 Year 15.09.12 48 GOOD 
3 C85246 Jagadeesan 47 M 01.08.12 09 Months 20.09.12 48 MILD 
4 C87229 Meghanadhan 51 M 01.08.12 01 Year 22.09.12 48 GOOD 
5 B78877 Yettiyappan 57 M 03.08.12 05 Years 21.09.12 48 GOOD 
6 C 80523 Leelavathi 48 F 06.08.12 01 Year 25.09.12 48 GOOD 
7 C82066 Ramesh 55 M 06.08.12 03 Years 25.09.12 48 GOOD 
8 C87632 Kavitha 34 F 07.08.12 05 Years 25.09.12 48 MODERATE 
9 B90712 Elizabeth Mary 47 F 21.08.12 02 Years 10.10.12 48 GOOD 
10 C92352 Sasikala 44 F 24.08.12 01 Year 12.10.12 48 MODERATE 
11 C95716 Josephin Mary 41 F 05.09.12 10 Years 25.10.12 48 GOOD 
12 C31382 Nazeer 60 M 30.08.12 10 Years 19.10.12 48 GOOD 
13 C93231 Kanniga 62 F 10.09.12 08 Years 29.10.12 48 GOOD 
14 C48875 Jambhulingam 60 M 01.09.12 02 Years 22.10.12 48 GOOD 
15 C95248 Suseela 50 F 06.09.12 10 Years 24.10.12 48 MODERATE 
16 C91495 Ranganathan 61 M 06.09.12 10 Months 25.10.12 48 MODERATE 
17 AR9161 Saradha 55 F 09.08.12 08 Years 29.09.12 48 GOOD 
18 C95197 Sumathi 50 F 08.09.12 11/2 Years 29.09.12 48 GOOD 
19 C97708 Parvathi 38 F 18.09.12 01 Year 05.11.12 48 GOOD 
20 C96778 Subramaniyam 52 M 20.09.12 01 Year 09.11.12 48 GOOD 
21 C80887 Muniyammal 43 F 22.07.12 08 Months 10.09.12 48 GOOD 
22 C85318 Thamizhselvi 38 F 22.07.12 01Year 14.09.12 48 MODERATE 
23 C82447 Selvi 32 F 24.07.12 01 Year 17.09.12 48 MODERATE 
24 C79569 Pugalendhi 38 M 24.07.12 03 Years 11.09.12 48 GOOD 
25 C82592 Kalarani 53 F 24.07.12 01 Year 10.09.12 48 GOOD 
26 C78485 Rosebabu 55 M 26.07.12 08 Months 20.09.12 48 GOOD 
27 C84995 Kasthoori 56 F 26.07.12 09 Months 13.09.12 48 MODERATE 
28 C38181 Revathy Sridhar 52 F 02.08.12 06 Years 22.09.12 48 GOOD 
29 C83812 Sumathi 47 F 26.07.12 08 Months 24.09.12 48 GOOD 
30 C83543 Karunanidhi 56 M 27.07.12 01 Year 20.09.12 48 GOOD 
31 C86074 Poongothai 55 F 30.07.12 10 Years 17.09.12 48 MILD 
32 C47715 Senthamaraiselvi 44 F 30.07.12 01 Year 24.09.12 48 MILD 
33 C85904 Lakshmiprabha 50 F 31.07.12 01 Year 17.09.12 48 GOOD 
34 C85223 Vijayalakshmi 32 F 31.07.12 08 Months 17.09.12 48 GOOD 
35 C83530 Sulochana 45 F 02.08.12 03 Years 24.09.12 48 MODERATE 
36 C84087 Arumugam 54 M 03.08.12 04 Years 24.09.12 48 GOOD 
37 C22005 Bama 50 F 04.08.12 02 Years 27.09.12 48 GOOD 
38 C85214 Malliga 48 F 02.09.12 03 Years 20.10.12 48 MODERATE 
39 C91616 Jeeva 47 F 01.09.12 01 Year 19.10.12 48 GOOD 
40 C95043 Chandra 48 F 08.09.12 02 Years 13.10.12 48 GOOD 
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Hb and RBC – INVESTIGATIONS BEFORE AND AFTER TREATMENT – IN IP & OP PATIENTS 
 
BT – BEFORE TREATMENT AT – AFTER TREATMENT
SL. 
NO OP/IP NO NAME 
Hb gm% TRBC Million/cumm 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
Treatment 
1. 4941 Gnanam 19.3 16.8 6.3 5.4 
2. 3993 Rajeshwari 13.8 14.0 4.2 4.4 
3. 4999 Jagadeesan 16.1 15.9 5.3 5.2 
4. 4994 Meghanadhan 13.1 14.0 3.7 4.0 
5. 5002 Yettiyappan 13.7 14.1 4.2 4.4 
6. 4048 Leelavathi 14.6 13.8 4.8 4.6 
7. 5010 Ramesh 14.7 14.9 4.6 4.6 
8. 4052 Kavitha 11.7 11.4 4.6 4.6 
9. 4092 Elizabeth Mary 14.0 12.0 4.6 4.6 
10. 4107 Sasikala 12.7 10.5 4.2 4.2 
11. 4158 Josephin Mary 12.9 13.6 4.6 4.8 
12. 5084 Nazeer 14.6 12.8 5.2 5.3 
13. 4170 Kanniga 12.9 11.0 4.4 4.5 
14. 5088 Jambhulingam 13.3 12.0 4.4 4.9 
15. 4161 Suseela 12.1 11.8 4.8 4.5 
16. 4071 Kasthuri 13.6 13.7 4.7 4.8 
17. 4058 Saradha 11.3 11.6 4.3 4.4 
18. 4165 Sumathi 14.3 14.5 4.6 4.5 
19. 4193 Parvathi 11.0 12.0 4.2 4.3 
20. 5152 Subramaniyam 13.0 11.3 4.2 4.1 
21. C80887 Muniyammal 13.6 14.0 4.6 4.8 
22. C85318 Thamizhselvi 14.8 15.5 5.0 5.1 
23. C82447 Selvi 12.2 12.5 4.3 4.3 
24. C79569 Pugalendhi 13.8 13.6 5.1 3.0 
25. C82592 Kalarani 13.9 14.2 4.7 4.5 
26. C78485 Rosebabu 15.8 15.8 5.3 5.3 
27. C91495 Ranganathan 14.1 14 5.3 5.1 
28. C38181 Revathy Sridhar 12.7 12.9 4.1 4.0 
29. C83812 Sumathi 12.2 12.8 4.2 4.4 
30. C83543 Karunanidhi 12.8 13.1 4.9 4.9 
31. C86074 Poongothai 13.0 12.8 4.3 4.2 
32. C47715 Senthamaraiselvi 10.0 12.3 4.8 4.2 
33. C85904 Lakshmiprabha 12.8 13.0 4.5 4.6 
34. C85223 Vijayalakshmi 11.5 12.0 4.2 4.6 
35. C83530 Sulochana 13.0 13.6 4.4 4.6 
36. C84087 Arumugam 13.2 13.7 4.6 4.6 
37. C22005 Bama 12.9 12.7 4.4 4.4 
38. C85214 Malliga 11.9 11.7 4.2 4.7 
39. C91616 Jeeva 14.5 12.2 5.2 5.0 
40. C95043 Chandra 13.0 14.0 4.3 4.2 
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CHOLESTEROL PROFILE OF THE OPD AND IPD PATIENTS (BEFORE AND 
AFTER TREATMENT) 
S.NO OP/IP NO 
T.CHOLESTEROL 
(mg/dl) HDL (mg/dl) LDL (mg/dl) 
VLDL 
(mg/dl) TGL (mg/dl) 
BT AT BT AT BT AT BT AT BT AT 
1. 4941 193 168 33 34 103 79 29 28 145 141 
2. 3993 183 128 32 36 106 73 27 31 136 158 
3. 4999 219 164 36 40 140 84 38 30 192 154 
4. 4994 150 155 29 28 75 84 49 20 241 101 
5. 5002 152 96 27 27 84 52 17 20 86 103 
6. 4048 203 154 38 38 136 79 27 37 136 185 
7. 5010 168 209 30 40 109 99 18 26 90 131 
8. 4052 191 199 35 40 122 100 12 18 64 94 
9. 4092 227 246 39 43 140 121 27 28 138 143 
10. 4107 127 133 30 32 98 73 17 21 86 106 
11. 4158 154 146 32 36 108 90 25 21 127 120 
12. 5084 164 184 28 35 84 87 30 33 154 167 
13. 4170 188 205 34 34 126 94 29 19 148 96 
14. 5088 158 172 37 34 67 76 14 25 72 126 
15. 4161 188 200 35 36 129 100 32 21 160 108 
16. 4071 219 253 31 45 110 126 34 28 173 144 
17. 4058 197 198 34 38 161 95 21 15 106 75 
18. 4165 156 140 34 36 89 80 43 38 217 196 
19. 4193 186 200 36 43 88 112 32 35 161 158 
20. 5152 190 238 30 43 96 111 38 37 192 186 
21. C80887 179 144 28 31 108 84 18 19 94 98 
22. C85318 177 212 30 43 126 106 23 22 118 114 
23. C82447 139 130 31 35 78 74 13 14 67 72 
24. C79569 180 169 35 34 100 117 33 27 166 137 
25. C82592 172 150 36 37 110 98 20 20 102 96 
26. C78485 179 157 28 32 97 79 17 18 85 93 
27. C91495 190 200 42 46 120 118 41 40 208 200 
28. C38181 110 149 21 30 42 72 09 14 47 73 
29. C83812 209 163 26 34 78 89 38 19 194 96 
30. C83543 156 163 39 32 88 72 14 14 73 71 
31. C86074 239 221 36 39 160 108 29 32 149 163 
32. C47715 184 200 38 35 73 96 29 26 145 133 
33. C85904 156 160 31 36 110 112 16 15 80 78 
34. C85223 186 170 37 40 129 110 20 20 103 98 
35. C83530 189 160 32 40 80 72 29 25 148 149 
36. C84087 213 218 34 40 109 106 47 28 238 144 
37. C22005 121 109 20 39 70 55 24 16 122 81 
38. C85214 184 196 27 36 164 94 20 25 103 128 
39. C91616 155 179 37 35 106 83 65 51 328 256 
40. C95043 244 168 45 48 132 140 57 32 286 141 
 
BT – BEFORE TREATMENT AT – AFTER TREATMENT 
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BLOOD INVESTIGATIONS BEFORE AND AFTER TREATMENT- IP PATIENTS 
 
 
 
 
 
 
S. 
NO 
IP. 
NO 
TC 
(million/                       
cu.mm) 
DC (%) ESR (mm/hr) 
N L E M 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 4941 11900 8900 74 71 20 24 6 5 - - 4/8 2/6 
2. 3993 10500 9900 72 77 25 20 3 3 - - 8/16 8/18 
3. 4999 5600 5700 62 63 33 33 5 4 - - 2/4 4/6 
4. 4994 4800 4900 57 56 36 37 5 6 2 1 8/20 4/16 
5. 5002 9400 9800 50 40 28 38 2 2 - - 4/10 4/16 
6. 4048 8200 7500 70 66 26 31 4 3 - - 6/12 10/26 
7. 5010 8700 9000 65 66 30 30 5 4 - - 2/4 8/20 
8. 4052 8000 9000 64 66 27 28 9 6 - - 26/42 6/26 
9. 4092 6800 6700 70 40 26 54 4 6 - - 2/6 2/4 
10. 4107 9300 9000 76 67 20 30 4 3 - - 14/28 2/4 
11. 4158 8600 8400 64 61 32 34 4 5 - - 8/28 4/8 
12. 5084 10100 10200 63 60 33 35 4 5 - - 6/22 4/8 
13. 4170 10700 11400 52 54 46 43 2 3 - - 6/24 4/8 
14. 5088 8100 6100 70 65 25 31 5 4 - - 4/8 2/10 
15. 4161 8500 9600 63 68 34 29 3 3 - - 10/32 2/10 
16. 4071 7600 7200 66 59 30 36 4 5 - - 30/62 12/44 
17. 4058 4000 7200 64 65 31 33 5 2 - - 6/14 26/62 
18. 4165 7700 8000 64 62 30 34 5 4 1 0 4/12 2/6 
19. 4193 7600 9800 64 65 33 30 3 5 - - 4/36 2/6 
20. 5152 6000 6300 54 50 42 45 4 5 - - 6/18 4/8 
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BLOOD INVESTIGATIONS BEFORE AND AFTER TREATMENT - OP PATIENTS 
 
 
 
S. 
NO 0P. NO 
TC 
(million/                       
cu.mm 
DC (%) ESR (mm/hr) 
N L E M 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. C80887 6700 7300 60 59 33 36 6 5 1 - 2/6 6/12 
2. C85318 6200 6300 57 63 37 35 6 2 - - 2/4 2/4 
3. C82447 6000 7200 60 65 33 30 5 5 - - 10/22 6/14 
4. C79569 7200 7800 50 56 42 39 7 5 1 - 12/14 4/16 
5. C82592 9500 9700 51 54 44 41 5 5 - - 4/12 2/6 
6. C78485 6100 6000 60 59 35 37 4 4 1 - 2/4 2/4 
7. C91495 7600 9300 67 72 27 23 6 5 - - 10/22 4/12 
8. C38181 6100 6200 47 52 35 33 17 01 01 14 10/22 6/16 
9. C83812 6800 7000 44 46 32 31 22 23 2 - 80/100 24/70 
10. C83543 7100 7100 65 61 30 34 5 5 - - 14/30 2/10 
11. C86074 5400 6600 55 62 38 33 5 5 2 - 4/12 2/4 
12. C47715 8800 6100 65 60 33 35 2 5 - - 2/6 2/6 
13. C85904 5200 6000 56 65 36 30 4 5 4 - 6/16 4/8 
14. C85223 7500 8000 65 63 30 32 5 5 - - 2/8 4/16 
15. C83530 12500 8500 42 56 41 36 17 6 - - 6/16 4/8 
16. C84087 4500 5300 50 55 44 40 6 5 - - 6/14 2/4 
17. 
C22005 
5900 5800 55 55 40 41 5 4 - - 6/16 4/12 
18. C85214 8000 8800 60 45 34 52 6 3 - - 10/20 2/4 
19. C91616 10500 9000 68 62 30 33 2 5 - - 8/16 2/6 
20. C95043 7400 8000 56 74 42 20 2 6 - - 14/44 6/12 
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SERUM BILIRUBIN BEFORE AND AFTER TREATMENT - IP PATIENTS 
  
 
 
Sl. 
No IP NO 
Serum bilirubin (mg/dl) 
Direct Indirect Total 
BT AT BT AT BT AT 
1. 4941 0.2 0.3 0.4 0.4 0.6 0.7 
2. 3993 0.2 0.2 0.3 0.1 0.5 0.3 
3. 4999 0.5 0.2 0.5 0.3 1.0 0.5 
4. 4994 0.6 0.3 0.6 0.4 1.2 0.7 
5. 5002 0.1 0.3 0.2 0.4 0.3 0.7 
6. 4048 0.2 0.2 0.4 0.3 0.6 0.5 
7. 5010 0.2 0.3 0.3 0.4 0.5 0.7 
8. 4052 0.2 0.2 0.1 0.3 0.3 0.5 
9. 4092 0.3 0.2 0.4 0.2 0.7 0.4 
10. 4107 0.2 0.3 0.4 0.5 0.6 0.8 
11. 4158 0.2 0.2 0.2 0.2 0.4 0.4 
12. 5084 0.3 0.2 0.4 0.3 0.7 0.5 
13. 4170 0.3 0.3 0.4 0.4 0.7 0.7 
14. 5088 0.4 0.3 0.5 0.5 0.9 0.8 
15. 4161 0.2 0.3 0.3 0.4 0.5 0.7 
16. 4071 0.4 0.3 0.5 0.4 0.9 0.7 
17. 4058 0.2 0.2 0.2 0.4 0.4 0.6 
18. 4165 0.2 0.1 0.2 0.2 0.4 0.3 
19. 4193 0.2 0.2 0.3 0.4 0.5 0.6 
20. 5152 0.2 0.2 0.3 0.3 0.5 0.5 
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SERUM BILIRUBIN BEFORE AND AFTER TREATMENT - OP PATIENTS 
 
 
S. 
No OP NO 
Serum bilirubin 
Direct Indirect Total 
BT AT BT AT BT AT 
1. C80887 0.2 0.2 0.4 0.2 0.6 0.4 
2. C85318 0.7 0.6 0.6 0.6 1.3 1.2 
3. C82447 0.2 0.2 0.4 0.3 0.6 0.5 
4. C79569 0.2 0.2 0.2 0.3 0.4 0.5 
5. C82592 0.2 0.2 0.4 0.3 0.6 0.5 
6. C78485 0.2 0.3 0.3 0.5 0.5 0.8 
7. C91495 0.2 0.2 0.2 0.2 0.4 0.4 
8. C38181 0.5 0.3 0.5 0.5 1.0 0.8 
9. C83812 0.2 0.2 0.3 0.3 0.5 0.5 
10. C83543 0.2 0.3 0.4 0.4 0.6 0.7 
11. C86074 0.2 0.2 0.3 0.4 0.5 0.6 
12. C47715 0.2 0.2 0.2 0.3 0.4 0.5 
13. C85904 0.2 0.2 0.3 0.3 0.5 0.5 
14. C85223 0.2 0.2 0.1 0.2 0.3 0.3 
15. C83530 0.2 0.2 0.3 0.2 0.5 0.4 
16. C84087 0.3 0.3 0.4 0.5 0.7 0.8 
17. C22005 0.2 0.2 0.2 0.4 0.4 0.6 
18. C85214 0.2 0.2 0.3 0.2 0.5 0.4 
19. C91616 0.2 0.2 0.3 0.3 0.5 0.5 
20. C95043 0.2 0.2 0.4 0.3 0.6 0.5 
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LIVER FUNCTION TESTS BEFORE AND AFTER TREATMENT - IP PATIENTS 
Sl. 
No IP NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumin 
(g/dl) 
Globulin 
(g/dl) 
T. Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 4941 36 29 38 30 232 191 4.2 3.6 2.6 3.0 6.8 6.6 
2. 3993 16 11 18 14 260 182 3.5 3.8 2.0 2.1 7.0 5.9 
3. 4999 20 16 21 18 174 155 4.1 4.0 2.3 2.2 6.4 6.2 
4. 4994 20 12 24 16 160 175 3.9 3.3 3.5 2.7 7.4 6.0 
5. 5002 27 20 24 23 165 166 4.3 3.8 3.1 3.1 7.4 6.9 
6. 4048 10 14 11 16 140 183 5.1 3.7 2.0 2.4 7.1 6.1 
7. 5010 51 11 45 13 220 156 4.2 3.7 3.0 2.8 7.2 6.5 
8. 4052 24 13 06 14 172 159 4.0 3.7 2.0 2.4 6.0 6.1 
9. 4092 91 53 122 71 220 260 4.1 4.3 3.0 2.0 7.1 6.3 
10. 4107 26 11 27 13 142 170 3.1 3.9 2.4 2.3 5.5 6.2 
11. 4158 12 21 14 30 150 146 3.2 3.1 2.0 2.4 5.2 5.6 
12. 5084 12 18 13 21 135 165 4.6 4.3 3.2 2.7 7.8 7.0 
13. 4170 20 11 22 12 196 143 4.0 3.2 2.0 2.5 6.0 5.7 
14. 5088 26 25 28 28 169 201 3.7 3.7 2.0 2.6 5.7 6.3 
15. 4161 13 12 14 14 183 153 3.8 3.4 2.8 3.0 6.6 6.4 
16. 4071 19 13 20 16 236 165 3.4 3.9 3.3 2.8 6.7 6.7 
17. 4058 22 12 23 14 175 130 4.1 3.7 2.0 2.3 6.1 6.0 
18. 4165 29 26 30 28 195 170 3.6 3.8 2.9 3.0 6.5 7.0 
19. 4193 12 12 14 13 156 160 3.9 3.0 2.8 2.6 6.7 5.6 
20. 5152 13 16 15 18 199 156 3.6 3.7 2.9 2.0 6.5 5.7 
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LIVER FUNCTION TESTS BEFORE AND AFTER TREATMENT - OP PATIENTS 
 
S. 
No OP NO 
SGOT 
(IU/dl) 
SGPT 
(IU/dl) 
Al.pho 
(U/dl) 
Albumin 
(g/dl) 
Globulin 
(g/dl) 
T. Protein 
(g/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. C80887 20 17 21 18 169 140 - 3.7 - 2.8 - 6.5 
2. C85318 12 10 13 12 156 176 3.6 5.0 3.0 2.0 7.2 7.0 
3. C82447 27 44 31 38 256 201 3.6 4.6 4.0 2.5 7.6 7.1 
4. C79569 24 20 28 22 193 166 3.2 3.9 2.6 2.8 6.5 6.7 
5. C82592 60 24 69 26 214 216 5.0 5.0 2.0 3.1 7.0 7.2 
6. C78485 26 15 27 17 156 166 4.0 4.1 2.3 2.3 6.3 6.4 
7. C91495 16 15 17 18 150 155 4.1 4.1 2.6 2.0 6.7 6.7 
8. C38181 20 10 21 12 176 186 3.0 3.8 2.0 2.8 5.0 6.6 
9. C83812 20 28 26 17 199 200 4.2 4.6 3.0 2.4 7.2 7.0 
10. C83543 30 18 32 20 249 172 3.3 3.7 4.1 2.8 7.4 6.5 
11. C86074 16 16 17 18 138 170 4.5 3.1 2.0 2.0 6.5 5.1 
12. C47715 23 25 29 27 198 151 3.7 4.2 3.1 2.3 6.8 6.5 
13. C85904 30 25 31 29 198 186 4.6 4.6 3.0 3.1 7.6 7.3 
14. C85223 14 18 15 20 150 156 4.9 4.6 3.0 3.0 7.9 7.4 
15. C83530 27 19 28 20 199 187 4.7 4.4 2.1 2.2 6.8 6.9 
16. C84087 30 23 31 25 186 140 5.1 4.8 2.0 2.7 7.1 7.5 
17. C22005 14 16 15 18 140 204 3.0 3.2 2.0 2.4 5.0 5.6 
18. C85214 24 35 25 24 170 170 3.6 3.8 2.7 2.0 6.4 5.8 
19. C91616 12 13 13 15 167 163 4.1 3.8 2.5 2.5 6.6 6.3 
20. C95043 24 20 26 24 189 180 3.0 3.6 2.1 3.0 5.1 6.6 
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URINE AND MOTIONS EXAMINATION BEFORE AND AFTER TREATMENT – IP 
 
S. 
NO IP NO 
URINE 
Before Treatment After Treatment 
Albumin Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus 
Cells 
Epi. 
cells 
Pus 
cells 
Epi. 
cells 
1. 4941 NIL NIL 2-6 1-2 NIL NIL 2-6 1-2 
2. 3993 NIL NIL 2-4 2-4 NIL NIL 3-4 3-4 
3. 4999 NIL NIL 1-2 2-4 NIL NIL 1-2 2-4 
4. 4994 NIL NIL 1-2 2-3 NIL NIL 2-4 1-2 
5. 5002 NIL NIL 1-2 1-2 NIL NIL 2-3 1-2 
6. 4048 NIL NIL 3-4 2-3 NIL NIL 3-4 3-4 
7. 5010 NIL NIL 1-2 1-2 NIL NIL 1-2 2-3 
8. 4052 NIL NIL 2-3 2-3 NIL NIL 2-3 2-3 
9. 4092 NIL NIL 2-3 3-6 NIL NIL 3-4 4-8 
10. 4107 NIL NIL 1-2 2-4 NIL NIL 1-2 2-4 
11. 4158 NIL NIL 3-4 2-4 NIL NIL 3-4 2-4 
12. 5084 NIL NIL 2-4 2-4 NIL NIL 1-2 2-4 
13. 4170 NIL NIL 3-4 2-4 NIL NIL 1-2 2-4 
14. 5088 NIL NIL 1-2 2-4 NIL NIL 2-3 2-4 
15. 4161 NIL NIL 4-5 3-4 NIL NIL 3-4 3-4 
16. 4071 NIL NIL 1-2 2-4 NIL NIL 2-4 2-4 
17. 4058 NIL NIL 2-3 6-8 NIL NIL 2-3 10-10 
18. 4165 NIL NIL       1-2 2-4 NIL NIL 1-2 2-4 
19. 4193 NIL NIL 1-2 2-4 NIL NIL 1-2 1-2 
20. 5152 NIL NIL 1-2 3-5 NIL NIL 2-3 3-5 
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URINE AND MOTIONS EXAMINATION BEFORE AND AFTER TREATMENT –OP 
 
S. 
NO OP NO 
URINE 
Before Treatment After Treatment 
Albumin Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus 
Cells 
Epi. 
cells 
Pus 
cells 
Epi. 
cells 
1. C80887 NIL NIL 3-6 4-5 NIL NIL 4-8 6-8 
2. C85318 NIL NIL 1-2 8-10 NIL NIL 1-2 10-12 
3. C82447 NIL NIL 8-10 4-5 NIL NIL 4-8 2-3 
4. C79569 NIL NIL 4-8 2-3 NIL NIL 4-8 2-3 
5. C82592 NIL NIL 1-2 1-2 NIL NIL 2-4 1-2 
6. C78485 NIL NIL 1-2 1-2 NIL NIL 2-3 2-4 
7. C91495 NIL NIL 1-2 2-4 NIL NIL 2-4 2-4 
8. C38181 NIL NIL 3-4 4-5 NIL NIL 4-5 3-4 
9. C83812 NIL NIL 3-6 3-4 NIL NIL 3-6 3-4 
10. C83543 NIL NIL 2-4 2-3 NIL NIL 2-4 1-2 
11. C86074 NIL NIL 2-4 3-5 NIL NIL 3-5 3-5 
12. C47715 NIL NIL 2-4 2-4 NIL NIL 1-2 2-4 
13. C85904 NIL NIL 1-2 2-4 NIL NIL 1-2 4-5 
14. C85223 NIL NIL 2-4 1-2 NIL NIL 2-4 1-2 
15. C83530 NIL NIL 2-4 1-2 NIL NIL 2-4 1-2 
16. C84087 NIL NIL 2-4 4-5 NIL NIL 2-4 4-5 
17. C22005 NIL NIL 4-5 10-12 NIL NIL 4-5 6-8 
18. C85214 NIL NIL 1-2 2-4 NIL NIL 1-2 2-4 
19. C91616 NIL NIL 8-10 4-5 NIL NIL 4-5 4-5 
20. C95043 NIL NIL 1-2 2-4 NIL NIL 1-2 2-4 
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Statistical Analysis: 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired ‘t’ test was performed for determining the significance between before and after 
treatment. 
Paired Samples Statistics 
 
Mean N Std. Deviation Std. Error Mean 
Pair 1 Bt 6.65 40 1.545 .244 
At 3.13 40 1.697 .268 
Paired Samples Test 
 t df Sig. (2-tailed) 
Pair 1 Bt - At 11.369 39 .001 
 
The mean± standard deviation of pain score at before and after treatment were 6.65 ± 1.55 and 3.13 ± 1.6 respectively which 
is statistically significant (t= 11.369 p<0.001). 
VARMAM: Report  
AT  
var Mean N Std. Deviation P value 
1 3.60 30 1.476 t=3.473 
<0.001 
2 1.70 10 1.567  
Total 3.13 40 1.697  
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DISCUSSION 
According to Siddha literature, Azhal Keel Vayu is one among the Keelvayu .It is 
characterized by pain, swelling and restricted movements. Sometimes it may lead to difficulty 
in walking. 
This condition can be correlated to Osteoarthritis in Modern Orthopaedics. 
Osteoarthritis is defined as a degenerative, non - inflammatory joint disease characterized by 
destruction of articular cartilage and formation of new bone at the joint surfaces and margins. 
A detailed study of the disease Azhal keel vaayu was done and was correlated to the 
signs and symptoms of Osteoarthritis in modern science. The Absent  clinical study was done 
as per the approved protocol and the data were collected by using the prescribed proforma 
from the 40 cases who were treated in the Inpatient ward and Outpatient department of 
Sirappu Maruthuvam. 
 Based on various criteria, the data were collected and tabulated. The criteria were the 
gender predominance, incidence of the disease with respect to age, kaalam, seasonal 
variation, clinical manifestation, relation to menstrual cycle, diet and the assessment of the 
outcome of the disease with the trial drug were observed. 
The trial drugs for this study were prepared by the Author in the Gunapadam practical 
laboratory of National Institute of Siddha, under the supervision of the members of the 
teaching faculty and guided by the Head of the Department of Sirappu Maruthuvam of the 
National Institute of Siddha, Chennai - 47.  
In Siddha system, before starting the treatment it is necessary to bring the Mukkutram 
to equilibrium. By giving purgation we can normalize the deranged Vaatham.  
                                  “Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ”  
The trial drugs Avuri Karpam (Internal) and Vatha Noikku Ennai (External) were 
given for 48 days.  Out-Patients were asked to visit the hospital once in 7 days. For Out-
Patients the drugs were given for 48 days and the clinical assessment was done on 0th day, 
12th day, 24th day, 36th day and 49th day.  
 For In-Patients the drugs were given for 48 days and the clinical assessment was 
done daily. 10 In-Patients were given Varmam treatment along with their trial drugs.  
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The results were compared at the end of the study. For In-Patients, who are not in a 
situation to stay in the hospital for a long time, were advised to attend the Out-Patient 
Department of Sirappu Maruthuvam for further follow- up. 
Patients were instructed to take the medicines regularly and apply the external 
medicine. It was ensured that the diet restrictions imposed were followed properly by the 
patients. 
After the treatment, the patients were advised to visit the Out-Patient ward of 
Department of Sirappu Maruthuvam for another 2 months for follow-up.  
Observations: 
· The majority affected sex is female (67.5%). The common cause for this may be 
depletion of calcium from their body, nutritional deficiency and increased house hold 
works. From history taking these were concluded as the reasons for female 
predominance. 
· This study shows that the highest incidence of Azhal keel vaayu is between 41-50 
years of age. 
· In this study, 87.5% of cases were reported from Neithal land. In Siddha literatures, it 
was mentioned that Neithal, which is responsible for Vaatha diseases. This study also 
emphasized the same. 
· Among 40 patients, 33 (82.5%) were non-vegetarians and 7 (17.5%) were 
vegetarians. 
· Mudhuvenil kaalam showed the highest incidence of 77.5% and   22.5% were 
reported during kaar kaalam. According to Siddha literature, the Vaatham humour 
attains Vertrunilai valarchi during kaar kaalam. Whereas in Mudhuvenil kaalam 
Vaatham attains Thannilai valarchi. 
· Viyanan, Samanan were affected in all 40 cases.  
· In all the cases the Sathaga pitham was affected.  
· Santhigam was affected in all the 40 cases. Santhiga kabam mainly lives in joints and 
so it was affected in all the cases. 
· Pulse reading (Naadi) was observed in all patients. 30 cases had Vaathapitham, 6 
cases had Pithavaatham. 
· In 32 cases oil spread slowly, in 8 cases it appeared like pearl. 
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· Enbu was affected in all the 40 cases (100%), Saaram was also affected in all the 40 
cases (100%), Oon and Kozhuppu was affected in all 40 cases (100 %), and there 
were no changes noted in other thathukkal like Moolai, Sukkilam and Suronitham. 
· Kaal was affected in all the 40 cases (100%). 
Clinical manifestations: 
Pain in the knee joint was Absent  in 40 cases. Swelling was Absent  in 12 cases. The 
other important features were morning stiffness in 10 cases, tenderness in 32 cases, restricted 
movements in 40 cases,  crepitation were observed in all 39 cases and deformity developed  
in 3 cases.                                              
Precipitating factors: 
Already it was explained that aging is the most common cause for Azhal keel vaayu. 
Apart from that, increased household works, Obesity and menopause are the other 
precipitating factors. 
Occupational references: 
Household work accounts for the highest number of 21 cases.  More weight bearing 
and improper positioning of knee are also the cause which leads to Osteoarthritis.   
Laboratory investigations: 
· By laboratory investigation ESR was found raised in early stages but after treatment it 
was found reduced. At the same time Total WBC counts, Total red blood cells were 
increased. In some cases haemoglobulin were increased and in some cases it was 
decreased. Total cholesterol and LDL were decreased in considerable cases. And 
HDL was increased. 
· Blood Urea and Serum Creatinine levels showed no changes in this study. 
· The radiographic studies showed narrowed joint space and presence of Osteophytes. 
The trial drug showed improvement in prognosis of the disease clinically rather than 
in radiographic changes. 
Treatment: 
    The treatment was aimed at normalizing the deranged mukkutram and providing relief 
from symptoms. Before treatment the patients were advised to take Agasthiyar kulambu - 130 
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mg with hot water in the early morning for purgation. The patient was advised to take rest 
without internal medicine on that day. 
The author treated the patients with trial drugs Avuri Karpam -1gm bid with honey 
(Internal) and Vatha Noikku ennai (External). During treatment, the patients were advised to 
follow Pathiyam (avoid tamarind, tubers etc.).  
 Effect of Treatment: 
 Good improvement was observed in 28 Patients, moderate improvement in 9 patients 
and mild improvement in 3 patients. The mean pain score before treatment was 6.65 and after 
treatment it was reduced to 3.13. The mean pain score before treatment patients who treated 
without varmam was 6.65 and after treatment it was reduced to 3.60. 
No toxic and side effects were clinically observed in all cases. 
Effect of varmam: 
10 IP patients are treated with Varmam along with the trial drug. The remaining 10 IP 
patients received only trial medicines. The results are compared at the end of the study. In 
this clinical trial, patients who treated with Varmam showed very good result in the marked 
reduction of pain. The mean pain score before treatment was 6.65 and after treatment it was 
reduced to 1.70 Hence this study reveals the importance of Varmam treatment in the 
treatment of Osteoarthritis.  
Evaluation of medicines: 
The preliminary phytochemical study revealed the presence of several phyto-
constituents. The test drug answered for the presence of calcium, ferrous iron, and phosphate, 
nitrate, reducing sugar, chloride and alkaloides. Repeated oral toxicity study conducted for15 
days with the drug did not exhibit significant changes in blood counts. The biochemical 
markers of liver function test did not show any evidence of liver toxicity. The biochemical 
markers of renal function test did not show any evidence of renal toxicity.  
There were no significant changes in biochemical parameters like blood cholesterol, 
body weight, food, water intake and behavioural parameters. 
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SUMMARY 
         The clinical study on Azhal keel vaayu with reference to its aetiology, pathogenesis, 
investigations, clinical features, diagnosis and treatment were conducted at the Sirappu 
maruthuvam Department, Ayothidoss Pandithar Hospital, National Institute of Siddha, 
Chennai – 47. 
The drugs administered in the clinical study were used only after careful purification 
process. 
40 cases of both the sexes (majority of females) with the signs and symptoms of 
Azhal keel vaayu were selected in the age group within 30 to 65 for the study. 10 cases in the 
In-Patient ward were given Varmam therapy along with the trial drugs and for the remaining 
10 In-Patients were given only the trial drugs for 48 days. 20 cases were treated in the Out-
Patient Department for 48 days only with the trial drugs. 
All the details about the study and the drugs were informed to the patients in their 
vernacular language, dietary and information sheet were given to them and signed consent 
forms were obtained from them.  Before starting the treatment, the blood samples of the 
selected patients were subjected to investigation. 
On the first day of the treatment, purgation was given by administering Agasthiyar 
kulambu – 130mg with hot water in the early morning to normalize the deranged kuttram.  
From the second day onwards, the patients were treated with the trial drugs Avuri 
karpam 1gm bid with honey was given internally and Vatha noikku ennai externally.   
        Every 8th day, the patients were assessed for clinical improvement and adverse 
effects. During the treatment before (0th day) and at the end of the treatment (48th day) the 
laboratory investigations were repeated. The x-ray of the Joints were taken .The improvement 
was assessed. 
During the course of treatment there were no adverse effects or unwanted drug 
reactions in Gastro intestinal tract, Respiratory system, Cardio vascular system and Excretory 
systems.  
The toxicological studies were carried out in animals and the reports showed no 
hepato and renal toxicity. 
10 IP patients are treated with varmam along with their trial medicine. The remaining 
10 IP patients didn’t received varmam treatment. The results are compared at the end of the 
study. The mean pain score of the 10 patients who received varmam treatment before 
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treatment is 6.65 and after treatment it is reduced to 1.70 Hence  varmam  treatment along 
with trial medicine is effective in the treatment of Osteoarthritis.  
The study results showed that 70 % had Good improvement, 22.5 % had Moderate 
improvement and 7.5 % had mild improvement. The pain assessment was done in all the 40 
patients participated in the trial using the universal pain assessment scale and at the end of the 
study the results showed, the mean pain score before treatment was 6.65 and after treatment it 
is reduced to 3.13. The restriction of movements after treatment was reduced in 31 cases and 
persists in 9 cases. 
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CONCLUSION 
The study results showed that 70 % had Good improvement, 22.5 % had Moderate 
improvement and 7.5 % had mild improvement. 
Varmam treatment along with the trial drugs showed good prognosis when compared 
to patients treated only with trial drugs. Hence the study reveals the importance of Varmam in 
treating Azhal keel vaayu.  
Clinically, no adverse effects were reported during the trial and the laboratory 
investigations were also within normal limits. So, the drug is assumed to be safe for humans. 
Acute toxicity study in animal models reveals that the trial drug “Avuri karpam” is 
safe.  The safety of the trial drug was also proved from this study.  
Hence the study concludes that, the trial drugs are clinically effective in reduction of 
pain, swelling, restriction of movements. 
Because of the encouraging clinical results, it could be concluded that “Avuri karpam 
(Internally)” and “Vatha Noikku Ennai (Externally)” are effective in the treatment of “Azhal 
keel vaayu” (Osteoarthritis).  
However further work with large number of patients should be carried out towards 
finding the ideal dose response.  
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BIOCHEMICAL ANALYSIS OF  AVURI KARPAM 
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA  
 
Test Drugs 
 
 The following medicine was used in the study was processed by the methods 
prescribed in standard text books of siddha medicines. 
Avuri karpam was prepared by the method prescribed in the text book of  Pathartha Guna 
Vilakkam pg.no.43  
Qualitative phytochemical analysis of Acidic/Basic radicals and constituents in test 
drugs 
Preliminary Qualitative analysis of drug –  Avuri karpam 
Procedure Observation Inference 
Test for Calcium : 2 ml of 
extract is taken in a clean 
test tube. To this add 2 ml 
of  4% ammonium oxide 
solution.   
 white precipitate is formed Presence of calcium  
Test for Sulphate : 2 ml of 
the extract is added to 5 % 
barium chloride solution. 
No white precipitate is 
formed  
Absence of Sulphate  
Test for Chloride : The 
extract is treated with Silver 
nitrate solution  
 White precipitate is formed Presence of Chloride 
Test for carbonate : The 
substance is treated with 
Conc. HCl. 
No effervescence is formed  Absence of carbonate 
Test for Starch : The 
extract is added with weak 
iodine solution  
No blue colour is formed Absence of starch  
Test for Iron (Ferric) : 
The extract is treated with 
glacial acetic acid and 
No blue colour is formed Absence of Ferric iron 
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potassium ferrocyanide  
Test for Iron (Ferrous) : 
The extract is treated with 
Conc. HNO3 and 
ammonium thiocynate 
Blood red colour is formed Presence of Ferrous iron 
Test for phosphate : The 
extract is treated with 
ammonium molybdate and 
conc. HNO3 
Yellow precipitate is 
formed 
Presence of phosphate 
Test for Tannic acid : The 
extract is treated with Ferric 
chloride  
 No Black precipitate is 
formed 
Absence of Tannic acid 
Test for Unsaturation : 1 
ml of Potassium 
permanganate solution is 
added to the extract.    
Does not get decolourised  Absence of unsaturated 
compound 
Test for saponins: Dilute 
extract+ 1ml of distilled 
water shake well. 
No Froth formation Absence of saponins 
Test for sugars :  
 Benedict method ; 5ml of  
Benedict solution heated 
gently then add 8 drops of 
diluted extract then heated 
in a boiling water bath. 
 
Molisch test; Dilute 
extract+2 drops of 
Molisch+3ml conc.H2SO4. 
No colour change occured 
 
 
 
    
 
 
 No Reddish violet zones 
appeared 
Indicates the Absence of 
sugar 
 
 
 
 
 
Absence of carbohydrate 
Test for steroids : 
Liberman Burchard test ; 
Dilute extract +2 ml acetic 
anhydride+conc.H2SO4 . 
No Formation of red colour  Absence of steroids 
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Test for amino acids: 
Dilute extract +2ml of 
Ninhydrin’s soln . 
Formation of  violet colour Presence of  amino acids 
Test for proteins: Biuret 
method ; 1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
Formation of deep blue  
colour 
Presence of proteins 
Test for Flavanoids : 
Dilute extract+ mg  
bits+2drops of conc.HCl  
and gently heated. 
Formation of pink colour Presence of Flavanoids 
 
Preliminary Qualitative Phyto chemical tests procedure and interpretation of results 
 
S.NO CONSITUENTS INFERENCE 
1.  Silicate Absent  
2.  Carbonate Absent  
3.  Chloride Present 
4.  Sulphide Absent  
5.  Iron Present 
6.  Alkaloids Absent  
7.  Copper Absent 
8.  Sodium Absent 
9.  Sulphate Absent 
10.  Phospate Present 
11.  Nitrate Absent 
12.  Oxalate Absent 
 
 
109 
 
13.  Fluoride Absent 
14.  Borate Absent 
15.  Lead Absent 
16.  Aluminium Absent 
17.  Zinc Absent 
18.  Calcium Present 
19.  Magnesium Absent 
20.  Ammonium Absent 
21.  Potassium Absent 
22.  Mercury Absent 
23.  Arsenic Absent 
24. Starch Absent 
25. Reducing sugar Absent 
26. Tannic Acid Absent 
27. Unsaturated compound Absent 
28. Amino Acid Present 
29. Type of compounds Absent 
30. Proteins   Present 
31. Flavanoides Present 
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NATIONAL INSTITUTE OF SIDDHA 
ACUTE TOXICITY STUDY OF AVURI KARPAM  
[WHO guidelines, 1993] 
Principle: 
    Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound the study duration will be 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 10 
Acclimatization Period : 7 Days 
Clinical dose   : 2.0 gms\day 
 
S.No Group No of mice 
1 Vehicle control (saline) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(0.036gm) 
10  (5 male, 5 female) 
 
Test Animals  
      Test animals were obtained from the animal laboratory of the King institute, Chennai 
and stocked at National institute of siddha, Chennai. All the animals were kept under standard 
environmental condition (27+ or – 2 degree c).The animals had free access to water and 
standard pellet diet (Sai Durga foods pvt.ltd, Bangalore).The principles of laboratory animal 
care were followed and the  Institutional ethical committee approved the use of animals and 
the study design. (1248/ac/09/CPCSEA/4-23 / 2011) 
 Route of administration: 
 Oral route was selected, because it is the normal route of clinical administration. 
 
  
 
 
111 
 
Test substance and vehicle 
       Avuri Karpam is Brown in colour.  The test substance is insoluble in water, in order to 
obtain and ensure the uniformity in drug distribution the drug is dissolved by aqueous Tween 
80 solution (10%).  
Administration of doses 
          Avuri karpam was suspended in aqueous Tween 80 solution (10%), with uniform 
mixing and it was administered to the groups in a single oral dose .The control groups were 
received equal volume of the vehicle. The animals were weighed before giving the drug. The 
dose level was calculated according to body weight, and surface area. Since the clinical dose 
was 2.0gms\day it was converted to animal dose (0.036gm) and then administered. The 
principle of laboratory animal care was followed. 
Observations 
 Observations were made and recorded systematically and continuously observed as 
per the guideline after substance administration. The animals were monitored for behavioural 
parameters like, 
1. Awareness 
- Alertness 
- Visual placing 
- Stereotype 
- Passivity 
2. Mood 
-  Grooming 
-  Restlessness 
-  Irritability 
-  Fearfulness 
3. Motor activity 
- Spontaneous activity 
- Reactivity 
- Touch response 
- Pain response.  
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Animals were observed for body weight and mortality for 14 days. If animals died 
during the period of study, the animals were sacrificed.  At the end of the 14th day all animals 
were sacrificed and necropsy was done. 
Body Weight 
 Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the end 
of the test, surving animals were weighed and sacrificed. 
Results:   
Avuri karpam at the dose 0.036gm/animal did not exhibit any mortality in mice. 
 No behavior changes were noted for the first 4 hours and for the next 24 hours and 
throughout the study period of 14 days. No weight reduction was noted before and after the 
acute study duration. Reflexes were found to be normal before and after the study. All other 
observations were found to be normal before and after the study. In Necropsy, the organs of 
the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, Kidney, 
Urinary bladder, Uterus all appeared normal. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM l - SCREENING AND SELECTION PROFORMA 
1.OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………       4.GENDER: …………....... 
5. OCCUPATION: ………………………………..      6.INCOME:   ………………… 
7. ADDRESS:    ……………………………………  
…………………………………… 
…………………………………… 
8. CONTACT NO:    …………………………………… 
INCLUSION CRITERIA: 
· Age : 30-65Yrs 
· Sex : Both male and female 
· Patients having symptoms of Pain, swelling, stiffness, crepitations, restricted 
movements of both knee joints. 
· Patients willing to undergo radiological investigation, Laboratory investigations 
(blood and urine). 
· Patients willing to sign the informed consent stating that he/she will conscientiously  
stick to the treatment during 48days but can opt out of the trial of his/her own 
conscious discretion. 
EXCLUSION CRITERIA: 
· Rheumatoid arthritis 
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· Tuberculosis knee 
· Septic arthritis 
· Gonococcal arthritis 
· Gout 
· Cardiac diseases 
· Hypertension 
· Diabetes mellitus 
· Use of Narcotics 
· Pregnancy and lactation 
· History of trauma 
· Patient with any other serious systemic illness 
ADMITTED TO TRIAL: 
   YES                          NO  
 
 
 
 IF YES,     
OPD                          IPD 
  
 
 
If yes, serial NO: 
 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM lI -HISTORY TAKING PROFORMA 
1. SERIAL NO: ……. 2.OP/IP NO: ....................................................   
3. NAME: ………………………………………… 4. AGE: …….. 5. GENDER: …….. 
5. OCCUPATION: ………………………………      6. INCOME:………………….. 
7. COMPLAINTS & DURATION:   
 
 
 
 
 
 
8. PERSONAL HISTORY: 
PERSONAL HABITS YES NO 
IF YES, 
DURATION/ 
QUANTITY 
Smoking    
Tobacco Chewing    
Alcoholism    
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9. HISTORY OF PREVIOUS ILLNESS: 
DRUG HISTORY: 
 
 
 
10. FAMILY HISTORY: 
 Whether this problem runs in family? 
  1. Yes                               2.No         
                                     If yes, mention the relationship of affected person(s) 
1._______________ 
   2._______________ 
3._______________ 
 
11.DIETARY HABIT:     
  1.Vegetarian              
 2.Non-vegetarian 
 
12. MENSTURAL HISTORY: 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM III - CLINICAL ASSESSMENT PROFORMA 
1. SERIAL NO. : …………………   
2.OP / IP NO. : ......................................   
3. NAME: ……………………………   4. AGE: ……     5.GENDER: ................. 
6. DATE OF ASSESSMENT   :     
0th day  8thday  15thday                   22ndday    
29th day  36th day  43rdday  49thday 
7. SIDDHA SYSTEM OF EXAMINATIONS: 
1. THEGI:  [BODY CONSTITUTION]  
1. Vathaudal 
2. Pithaudal 
3. Kabaudal 
4. Thonthaudal 
2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
 1. Kurinji (Hilly terrain)                                   
 2. Mullai (Forest range)                       
 3. Marutham  (Plains)                            
4. Neithal (Coastal belt)                    
 5. Paalai (Arid regions)  
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3. KAALAM: 
1. Kaarkaalam     4. Pinpanikaalam 
2. Koothirkaalam    5.Ilavenilkaalam 
3. Munpanikaalam    6. Muthuvenilkaalam 
4. GUNAM: 
 1.Sathuvam  2.Raasatham     3.Thaamatham 
5. AIMPORIGAL (SENSORY ORGANS): 
 0thday 8thday 15thday 22ndday 29thday 36thday 43rdday 49thday 
Mei         
Vaai         
Kann         
Mookku         
Sevi         
6. KANMENDHIRIYAM (MOTOR ORGANS): 
 0thday 8thday 15thday 22ndday 29thday 36thday 43rdday 49thday 
Kai         
Kaal         
Vaai         
Eruvai         
Karuvai         
 
7. KOSANGAL (SHEATH): 
 Before treatment After treatment 
Annamaya 
kosam   
Pranamaya 
kosam   
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Manomaya 
kosam   
Vignanamaya 
kosam   
Ananthamaya 
kosam   
8. UYIR THAATHUKKAL: [THREE HUMOURS – VATHAM,  PITHAM,  KABAM] 
A) VALI 
 0th day 8th day 15th day 22nd day 29th day 36th day 43rd day 49th day 
Praanan         
Abaanan         
Udhaanan         
   Viyaanan         
Samaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
 
 
B) AZHAL 
 0th day 8th day 15th day 22nd day 29th day 36th day 43rdday 49th day 
Analam         
Ranjakam          
Saathakam          
Prasakam          
Aalosakam         
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C) IYAM 
 0th day 8th day 15th day 22nd day 29th day 36th day 43rdday 49th day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS) 
 Before treatment After treatment 
Saaram NORMAL/AFFECTED  
Senneer NORMAL/AFFECTED  
Oon NORMAL/AFFECTED  
Kozhuppu NORMAL/AFFECTED  
Enbu NORMAL/AFFECTED  
Moolai NORMAL/AFFECTED  
Sukkilam/ 
Suronitham 
NORMAL/AFFECTED   
10. ENVAGAI THERVU:  
I. NAADI: [PULSE PERCEPTION]         
Days Naadi 
0th  day  
8th day  
15th  day  
22nd day  
29th  day  
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36th  day  
43rd  day  
49th  day  
II. SPARISAM: [PALPATION] 
Day TENDERNESS TEMPERATURE 
0th  day   
8th day   
15th  day   
22nd  day   
29th  day   
36th  day   
43rd  day   
49th  day   
III. NAA:[TONGUE] 
Days NAA 
0th  day  
8th day  
15th  day  
22nd day  
29th  day  
36th  day  
43rd  day  
49th  day  
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IV.NIRAM: [COMPLEXION]   
 1. Vatham         
 2. Pitham 
 3. Kabam 
V.MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
VI.VIZHI: [EYES] 
Days Vizhi 
0th  day  
8th day  
15th  day  
22nd  day  
29th  day  
36th  day  
43rd  day  
49th  day  
VII. MALAM: [BOWEL HABITS / STOOLS] 
 0thday 8thday 15thday 22ndday 29thday 36thday 43rdday 49thday 
Niram         
Edai         
Irugal         
Ilagal         
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VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
NEIKKURI: 
Neikkuri Before treatment After treatment 
Snake like 
pattern 
  
Annular/Ringed 
pattern   
Pearl beaded 
pattern 
  
Other specific 
pattern   
 Before treatment After  treatment 
Height (cms)   
Weight (kg)   
Temperature(°F)   
Pulse rate(/min)   
Heart rate(/min)   
Respiratory rate(/min)   
Blood pressure(mm/Hg)   
Pallor   
Jaundice   
Cyanosis   
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11. GENERAL EXAMINATION 
 
12. SYSTEMIC EXAMINATION 
 Before treatment After treatment 
Cardiovascular 
System 
  
Respiratory system   
Gastrointestinal 
system 
  
Central Nervous 
System   
Urogenital system   
Endocrine 
System 
  
13. LOCOMOTOR SYSTEM: 
 CLINICAL SYMPTOMS: 
Affected knee joints: Right Left    Both               
Pain in knee joint: Mild Moderate   Severe 
Onset:                             Sudden                   Gradual 
 
 
  
Lymphadenopathy   
Pedal edema   
Clubbing   
Jugular vein pulsation   
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14. CLINICAL EXAMINATION OF KNEE JOINT   
I.INSPECTION: 
 0th day 8th day 15th day 22ndday 29th day 36th day 43rdday 49th day 
Attitude:         
swelling         
Skin over the 
knee joints         
Muscle 
wasting 
        
Deformity 
 
        
II.PALPATION: 
 0th day 8th day 15th day 22th day 29th day 36th day 43rdday 49th day 
Tenderness         
Crepitation         
Local heat         
 
III. MOVEMENTS 
 0th day 8th day 15th day 22ndday 29th day 36th day 43rdday 49th day 
Flexion         
Extension         
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IV. JOINT MESUREMENT: 
A. HEALTH ASSESSMENT QUESTIONNAIRE: 
 
 
 
 
 
 
 
 0th day 8th day 15th day 22ndday 29th day 36th day 43rdday 49th day 
PAIN 
A. Onset: 
Sudden/Gradual 
        
B. Early morning  
Stiffness (Absent 
/absent) 
        
C. Nature of pain                                             
(Mild/ Moderate/ 
Severe) 
        
D. Aggravating   
factor- 
Movement  
(Yes/No) 
        
E. Relieving factor 
–Rest 
(Yes/No) 
        
G. Tenderness 
(Absent /absent) 
        
RESTRICTION 
OF MOVEMENT  
(Fully/Partial/No) 
Knee joints 
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B. UNIVERSAL PAIN ASSESMENT SCALE: 
 
  Grade   0    :  No Pain 
  Grade 1 -3 :   Mild pain 
  Grade 4-6 :   Moderate pain 
             Grade 7-10 :   Severe pain     
C. RESTRICTED MOVEMENT ASSESSMENT SCALE:                
Gradation: 
Grade 1 - Fit for all activities, do their work without support. 
Grade II - Mild pain Absent  in knee joint, mild restricted movements. 
Grade III - Pain Absent  in knee joint, moderate restriction of movements. 
Grade IV - Severe pain, bed ridden. 
(Ref: Clinical manual for nursing practice (National Institute of Health Warren Grant 
Magnuson Clinical Centre) 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
VARMAM THERAPY – OBSERVATION CHART. 
                                  ASSESSMENT FORM 
  SL NO:              
  NAME:                   
  AGE/SEX:                  
  DATE:                  
  ADDRESS: 
COMPLAINTS AND DURATION: 
 
 
VARMAM POINTS MANIPULATED: 
§ Kaal Moottu Varmam (Varma Viralalavu Nool) 
§ Komberi (Varmasoothiram 101) 
§ Viruthi (Varmalaadasoothiram 300) 
§ UllangalVellai(Adivarmasootcham 500)                
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SL.
NO  
DATE PAIN TENDERNESS STIFFNESS 
 
DURATION OF 
RELIEF 
OTHER CLINICAL 
FEATURES 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20 
      
21 
      
22       
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23       
24       
25       
26       
27       
28       
29       
30       
31       
32       
33       
34       
35       
36       
37       
38       
39       
40       
41       
42       
43       
44       
45       
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46 
 
 
 
     
47       
48 
 
 
     
 
 
 
OTHER REMARKS: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:        Signature of the H.O.D 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
1. SL NO: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: ................. 
A.BLOOD INVESTIGATIONS: 
BLOOD INVESTIGATIONS NORMAL VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb( gm/dl) M:13-18 
W:11-16 
  
T.RBC(millions cells /Cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
ESR (mm) 
½ hr. -   
1 hr. M:0-10 
W:0-20 
  
T.WBC (Cells /Cu.mm) 4000-11000   
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
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BLOOD INVESTIGATIONS NORMAL VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood 
glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-200   
HDL 30-60   
LDL Up to 130   
VLDL 40   
TGL Up to 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-0.2   
Indirect bilirubin 0.2-0.7   
Total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT (IU/L) 0-40   
SGPT (IU/L) 0-35   
Alkaline phosphatase (IU/L) 80-290   
 
Serum calcium 9-11   
Serum phosphorus 2-5   
Serum Uric acid M:3-9 
W: 2.5-7.5 
  
 CRP   
 ASO titre   
 RA factor   
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B.URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS BEFORE TREATMENT AFTER TREATMENT 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
Bile salts   
Bile pigments   
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: Knee joint: 
1. Antero posterior  
2. Lateral view 
 
 
 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to my 
satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the   right to 
withdraw from the study at any time without in any way it affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.”                                                   
 
Date: 
 
 Signature of a witness     Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant: 
Signature of the Investigator: 
 Signature of the Lecturer:                                                            Signature of the HOD 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É, 
¦ºý¨É-47 
«Æø ¸£øÅ¡Ô §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý («×Ã¢ ¸üÀõ ÁüÚõ Å¡¾ §¿¡öìÌ 
±ñ¨½ö) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø  ÀÊÅõ. 
´ôÒ¾ø  ÀÊÅõ 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
¿¡ý þó¾ ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌô  ÒÃ¢Ôõ 
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 §¾¾¢ :                                                      ¨¸¦Â¡ôÀõ: 
 þ¼õ:                                                      ¦ÀÂ÷     : 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
 
±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ ÁÕòÐÅ 
ÅÆ¢Ó¨Èô ÀüÈ¢Ôõ,  ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ì ¸ñ¸¡½¢ì¸×õ, «¾¨Éô  
À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ô  ÀÃ¢§º¡¾¨É¸û ÀüÈ¢   ¾¢Õô¾¢ «Ç¢ìÌõ 
Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð. ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢ ±ý ¦º¡ó¾ 
Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É þó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ 
ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý. 
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐì ¦¸¡ûÙõ ¯Ã¢¨Á¨Âò 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
               ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ò §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ «Æø ¸£øÅ¡Ô 
§¿¡öì¸¡¸ «×Ã¢¸üÀõ(¯ûÁÕóÐ) ÁüÚõ Å¡¾§¿¡öìÌ ±ñ¨½ö(¦ÅÇ¢ÁÕóÐ)  
ÁÕóÐ¸Ç¢ý  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ 
´ôÒ¾ø «Ç¢ì¸¢§Èý. 
 §¾¾¢:                                                        ¨¸¦Â¡ôÀõ: 
þ¼õ:                                                          ¦ÀÂ÷     : 
 
§¾¾¢:                             º¡ðº¢ì¸¡Ã÷  ¨¸¦Â¡ôÀõ: 
þ¼õ:                                                     ¦ÀÂ÷ :                                                                          
¯È×Ó¨È         :   
 
Å¢Ã¢×¨ÃÂ¡Ç÷ ¨¸¦Â¡ôÀõ: 
 
Ð¨Èò¾¨ÄÅ÷¨¸¦Â¡ôÀõ:   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM VI - WITHDRAWAL FORM 
SI NO: 
OP /IP NO:           
NAME: 
AGE/GENDER :                
DATE OF TRIAL COMMENCEMENT:  
DATE OF WITHDRAWAL FROM TRIAL:  
REASONS FOR WITHDRAWAL: 
· Long absence at reporting :                                   Yes/ No 
· Irregular treatment:                                                Yes/ No 
· Shift of locality :                                                    Yes/No 
· Increase in severity of symptoms:                         Yes/No 
· Development of severe adverse drug reactions:    Yes/No 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM VII – PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.G.Suganya 
Name of the institute:  National Institute of Siddha, 
     Tambaram Sanatorium, 
     Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
I, Dr.G.Suganya studying M.D Siddha at National Institute of Siddha, Tambaram 
Sanatorium is doing a clinical trial on ‘‘Azhal Keel Vayu’’ (Osteoarthritis). Osteoarthritis is a  
common degenerative disease, occurring throughout the world. 
In this regard, I am in a need to ask you few questions. I will maintain confidentiality 
of your comments and data obtained. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. Taking 
part in this study is voluntary. No compensation will be paid to you for taking part in this 
study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
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             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
‘‘Avuri Karpam’’(Internal medicine) 1gm BD with Honey for 48 days) and ‘‘Vatha Noikku 
Ennai’’(External medicine). If you wish to stay in the In- Patient ward Varmam Treatment 
will be given to you assuring that you will not be definitely hurt in any course of treatment. 
 The information I am collecting in this study will remain between you and the 
principal investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. I will use a code instead.  
The questionnaire will take approximately 20 minutes. 
If you want to know more about this study before taking part, you can ask me 
(Dr.G.Suganya, PG Scholar cum principal investigator of this study, attached to National 
Institute of Siddha, Chennai-47). You can also contact the Member-secretary of Ethics 
committee, National Institute Siddha, Chennai 600047, for rights and participation in the 
study.  
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ,  
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É, 
¦ºý¨É-47. 
 
«Æø ¸£øÅ¡Ô §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý («×Ã¢ ¸üÀõ ÁüÚõ Å¡¾ §¿¡öìÌ 
±ñ¨½ö) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø  ÀÊÅõ. 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷  : ÁÕòÐÅ÷.¸.Í¸ýÂ¡ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷  :   §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
        ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
       ¦ºý¨É- 47 
 §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý  
(ÁÕòÐÅ÷.¸.Í¸ýÂ¡) «Æø¸£øÅ¡Ô ±ýÛõ ãðÎ¸¨Ç À¡¾¢ìÌõ §¿¡öì¸¡É ÁÕòÐÅ 
¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý.               
«Æø¸£øÅ¡Ô ±ýÛõ §¿¡Â¡ÉÐ ±ÖõÒ §¾öÁ¡Éò¾¡Öõ ±ÖõÒ¸ÙìÌ þ¨¼§Â 
þ¨¼¦ÅÇ¢ Ì¨ÈÅ¾¡Öõ ÓÆí¸¡ø ãðÎ¸Ç¢ø ¯ûÇ ¦¿öôÒò¾ý¨Á Ì¨ÈÅ¾¡Öõ 
¯ñ¼¡¸¢ÈÐ. þÐ ÓÆí¸¡ø ãðÎ¸Ç¢ø ÅÄ¢,Å£ì¸õ,ãðÎ¸¨Ç ¿£ð¼ Á¼ì¸ 
º¢ÃÁõ,¿¼ôÀ¾¢ø º¢ÃÁõ,¸¡¨Ä §¿Ãí¸Ç¢ø Å¢¨ÈôÒò¾ý¨Á Ó¾Ä¢Â ÌÈ¢Ì½í¸¨Çì 
¦¸¡ñ¼ §¿¡ö 
þÐ ÀÃÅì ÜÊÂ §¿¡ö «øÄ. 
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þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ 
«×Ã¢ ¸üÀõ1¸¢ §¾É¢ø Ì¨ÆòÐ 2 §Å¨Ç (¸¡¨Ä, Á¡¨Ä) ¯½×ìÌô À¢ý ´Õ Áñ¼Äõ 
(48¿¡ð¸û) ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ ÁÕó¾¡¸ Å¡¾ §¿¡öìÌ ±ñ¨½ö 48 
¿¡ð¸ÙìÌ §¿¡ÔûÇ ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. §¾º¢Â º¢ò¾ ÁÕòÐÅ 
¿¢ÚÅÉò¾¢ý ÁÕóÐ ¦ºöÓ¨È Ü¼ò¾¢ø þõÁÕó¾¡ÉÐ º¢ò¾ ÁÕòÐÅ÷¸Ç¢ý §¿ÃÊ 
§ÁüÀ¡÷¨ÅÂ¢ø ¦ºöÂôÀðÎûÇÐ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7 ¿¡ð¸ÙìÌ ´ÕÓ¨È 
ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. ¯û §¿¡Â¡Ç¢Â¡¸ ¾í¸ Å¢ÕôÀõ ¦¾Ã¢Å¢ìÌõ Àðºò¾¢ø 
§¿¡öìÌò ¾Ìó¾ Å÷Áî º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
þó¾ ÁÕóÐ º¢ÈôÀ¡¸ «Æø ¸£øÅ¡Ô§¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ 
áÄ¢ø ÜÈôÀðÎûÇÐ. 
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç «ÛÁ¾¢ò¾ô À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ ø¨Ä¦ÂÉ¢ø 
±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¬Ã¡öîº¢Â¢ø þÕóÐ Å¢Ä¸¢ì ¦¸¡ûÇ ¯Ã¢¨Á ¯ûÇÐ. 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ ÁüÈ Å¢ÀÃí¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷:¸.Í¸ýÂ¡(Àð¼ §ÁüôÀÊôÒ Á¡½Å÷ º¢ÈôÒ ÁÕòÐÅò Ð¨È) 
«Å÷¸¨Ç ±ó¾ §¿Ãò¾¢Öõ ¦¾¡¼÷Òì ¦¸¡ûÇÄ¡õ. ¨¸ô§Àº¢ ±ñ 9003541718. 
 
§ÁÖõ  þó¾ ¬Ã¡öîº¢ìÌò ¾ì¸ «ÛÁ¾¢î º¡ýÚ (IEC) ¦ÀÈôÀðÎûÇÐ. 
þó¾ ÁÕóÐ ÓüÈ¢Öõ À¡Ð¸¡ôÀ¡É ãÄ¢¨¸¸¨Çì ¦¸¡ñÎ ¾Â¡Ã¢ì¸ôÀðÎûÇÐ. Àì¸ 
Å¢¨Ç×¸¨Ç ²üÀÎò¾¡Ð. 
§ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ  ¸¡ìÌÁ¡Ú «È¢×Úò¾ô 
ÀÎ¸¢ÈÐ. 
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É ¯Ú¾¢ 
«Ç¢ì¸¢§Èý. 
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ô À¼ Á¡ð¼¡Ð. 
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM VIII- DRUG COMPLIANCE FORM 
SERIAL NO:     OP/IP NO: 
NAME:     AGE/ GENDER: 
DRUG NAME:  Avuri Karpam                FOR Out Patients: 
On 1st     day-Date:  Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 8th   day-Date:   Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 15th day-Date:         Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 22th day-Date:         Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 29th day-Date:          Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 36th day-Date:          Drugs issued: 14(Gms) Drugs returned: (Gms) 
On 43th day-Date:          Drugs issued: 14(Gms) Drugs returned: (Gms) 
FOR In - Patients: 
Day Date Morning Evening Day Date Morning Evening 
Day 1    Day 2    
Day 3    Day 4    
Day 5    Day 6    
Day 7    Day 8    
Day 9    Day 10    
Day 11    Day 12    
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Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD  
Day 13    Day 14    
Day 15    Day 16    
Day 17    Day 18    
Day 19    Day 20    
Day 21    Day 22    
Day 23    Day 24    
Day 25    Day 26    
Day 27    Day 28    
Day 29    Day 30    
Day 31    Day 32    
Day 33    Day 34    
Day 35    Day 36    
Day 37    Day 38    
Day 39    Day 40    
Day 41    Day 42    
Day 43    Day 44    
Day 45    Day 46    
Day 47    Day 48    
Day 49        
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM IX - DIETARY ADVICE FORM 
§º÷ì¸ì ÜÊÂ ¯½×¸û (Diet to be included): 
¸¡ö¸û (Vegetables): 
 ¸ò¾Ã¢ôÀ¢ïÍ (Unripe brinjal) 
 ÓÕí¨¸ôÀ¢ïÍ (Unripe drumstick) 
 «Å¨ÃôÀ¢ïÍ (Unripe Dolichos bean) 
¸£¨Ã¸û(Greens): 
 ¦À¡ýÉ¡í¸ñ½¢ (Sessile plant [Alternanthera sessilis] ) 
 ãì¸¢Ãð¨¼ (Hog weed [Boerhaavia diffusa] ) 
 àÐ§Å¨Ç (Climbing brinjal [Solanum trilobatum] ) 
 ÓÕí¨¸ì¸£¨Ã (Leaves of Drumstick [Moringa oleifera] ) 
 ¸È¢§ÅôÀ¢¨Ä (Curry leaf [Murraya koenigii] ) 
 Ó¼ì¸Úò¾¡ý (Winter cherry [Cardiospermum halicacabum] ) 
 «Ú¸£¨Ã (Amaranthus tristis) 
 ¸Ã¢º¡¨Ä (trailing eclipta [Eclipta prostrate] ) 
ÀÆí¸û(Fruits): 
Á¡Ð¨Ç (Pomegranate) 
¬ôÀ¢û (Apple) 
ÀôÀ¡Ç¢ (Papaya) 
¬ÃïÍ (Orange) 
§ÀÃ£î¨º (Dates) 
«ò¾¢ (Fig) 
¿¡Åø (Jambul [Syzygium cumini] ) 
«¨ºÅõ (Non-vegetarian diet): 
  ¦ÅûÇ¡ðÎì¸È¢ (Meat)  
  ¸¡¨¼ (Quail) 
  º¢Ú þÈ¡øÁ£ý (Prawn) 
 
 
144 
 
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û (Diet to be avoided): 
  Í¨Ã (Bottle gourd)                              
  âº½¢ (Pumpkin)                             
  ¦ÅûÇÃ¢ì¸¡ö (Cucumber)             
Ò¼¨Ä (Snake gourd) 
À£÷ìÌ (Ridged gourd)    
 ¯ÙóÐ (Black gram)                                                
¦Á¡î¨º (Indian butter Bean) 
¸¡Ã¡Á½¢ (Cow gram) 
¦¸¡ûÙ (Horse gram)                       
¸ÎÌ (Mustard)                          
±ñ¦½ö (Gingelly oil)         
ÒÇ¢ôÒ (Sour)   
¯ôÒ (Salt)           
Å¡Ôô ¦À¡Õð¸û (Vatha diet)  
¯Õ¨Çì ¸¢ÆíÌ (Potato) 
Å¡¨Æì ¸¡ö (Plantain) 
Ò¨¸Â¢¨Ä (Tobacco)      
ÁÐ «ÕóÐ¾ø (Alcohol) 
¦Àñ§À¡¸õ (þîº¡ Àò¾¢Âõ) [Sexual intercourse] 
ÁÕòÐÅ «È¢×¨Ã: 
®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ, 
  ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É þ¼ò¾¢ø þÕôÀ¨¾ò ¾Å¢÷ì¸×õ. 
¯¼ø «¾¢¸ ±¨¼ þÕôÀ¢ý ±¨¼¨Âì Ì¨Èì¸ §ÅñÎõ. 
«¾¢¸ àÃõ ¿¼ò¾ø, «¾¢¸ §¿Ãõ ¿¢üÈø ¾Å¢÷ì¸×õ. 
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       NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AVURI KARPAM” (INTERNAL) AND 
“VATHA NOIKKU ENNAI” (EXTERNAL) FOR THE TREATMENT OF “AZHAL 
KEEL VAYU” (OSTEOARTHRITIS-KNEE JOINT). 
FORM X - ADVERSE REACTION FORM 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                    AGE:                                          GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:  TIME: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
MANAGEMENT: 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD  
